Top

Shimin Hu, M.D., Ph.D.

Department of Hematopathology, Division of Pathology-Lab Medicine Div

Present Title & Affiliation

Primary Appointment

Associate Professor (with tenure), Department of Hematopathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1998	The University of Michigan, Ann Arbor, Michigan, US, Ph.D. (Molecular and Cellular Pathology)
1993	Peking University, Beijing, CN, MD

Postgraduate Training

2011-2013	Clinical Fellow, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2008-2011	PGY2-4 Resident, Anatomic and Clinical Pathology, Hartford Hospital, Hartford, Connecticut
2007-2008	PGY1 Resident, Anatomic and Clinical Pathology, The University of Toledo, Toledo, Ohio
1999-2003	Postdoctoral Research Fellow, The University of Pennsylvania, Philadelphia, Pennsylvania
1998-1999	Postdoctoral Research Fellow, Mayo Clinic, Rochester, Minnesota

Licenses & Certifications

2013	Texas Medical Board
2012	American Board of Pathology, Hematology
2011	American Board of Pathology, Anatomic and Clinical Pathology

Experience & Service

Faculty Academic Appointments

Assistant Professor (tenure track), Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2020

Senior Research Associate, Department of Cancer Biology, The University of Pennsylvania, Philadelphia, Pennsylvania, 2003 - 2005

Intramural Institutional Committee Activities

Member (Review the candidate’s CV, synopsis, and academic profile; summarize their strengths and weaknesses, and provide recommendations for improvement), Mid-Term Tenure Track Review Committee (for Sofia Garces), The University of Texas MD Anderson Cancer Center, 2025 - 2025

Member, Committee on Educational Offerings and Educator Enhancement, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member (Review posters in translational research for Best Abstract Award), Scientific Judge Committee, PLM Annual Research Day, The University of Texas MD Anderson Cancer Center, 2024

Member (Interrogate sample availability in the Institutional Tissue Bank for feasibility and scientific review of the proposed use), Data & Biospecimen Access Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member (Review for Trainee Research Day Best Abstract Award, Endowed Fellowships Award, and Distinguished Faculty Mentor Award), Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2025

Member, Divisional Diversity, Equity, and Inclusion Committee, Division of PLM, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, Thesis Committee for MS Student Linda Tholath, The University of Texas MD Anderson Cancer Center, 2020 - 2022

Member (Review 5-6 proposals in hematologic malignancies for intramural grants each year), Institutional Research Grant Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2019

Extramural Institutional Committee Activities

Chair, Award Committee, Chinese American Pathologist Association, 2025 - 2026

Chair, Award Committee, Chinese American Pathologist Association, 2024 - 2025

Board Director, Board of Directors, Chinese American Pathologist Association, 2021 - 2023

Editorial Activities

Editorial Board, Acta Haematologica, 2023 - Present

Topic Editor, Frontiers in Oncology, 2023 - 2024

Editorial Board, Journal of Hematology, 2019 - Present

Associate Editor, Frontiers in Oncology, 2019 - Present

Editorial Board, American Journal of Clinical Pathology, 2018 - 2019

Editorial Board, Leukemia Research, 2018 - Present

Honors & Awards

2025 - Present	Chinese American Pathologist Association (CAPA) Service Award, Chinese American Pathologist Association
2024 - Present	Invited to participate in Project EVOLVE, NCI/NIH
2024	The Most Scholarly Activity Award, The University of Texas Health Science Center at Houston
2022	Winship Elkin Lecture, Winship Cancer Institute, Emory University
2021	Invited to contribute to the update of the 5th edition WHO Classification of Hematolymphoid Tumors, World Health Organization
2020	CAPA-GoPath Best Abstract Award, 1st Place, Chinese American Pathologist Association
2017	ASH Abstract Achievement Award, American Society of Hematology
2017	Faculty Spotlight, The University of Texas MD Anderson Cancer center
2017	The Shannon Timmins Fellowship for Leukemia Research, The University of Texas MD Anderson Cancer Center
2016	AGT Student Research Award, Association of Genetics Technologists
2016	The Kimberly Patterson Endowed Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center
2016	CAPA/GoPath Best Abstract Award, 1st Place, Chinese American Pathologist Association
2016	Platform Competition, 1st Place, Texas Society of Pathologists
2015	Best Poster Award, 3rd Place, Society of Hematologic Oncology
2013	The Kimberly Patterson Endowed Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center
2013	CAPA/GoPath Best Abstract Award, 1st place, Chinese American Pathologist Association
2012	Best Poster Merit Award, Society of Hematologic Oncology
2012	Pathology Research Fellowship Award, Division of PLM, The University of Texas MD Anderson Cancer Center
2012	Pathology Research Fellowship Award, Division of PLM, The University of Texas MD Anderson Cancer Center

Professional Memberships

International Academy of Clinical Hematology

2019 - Present

Society of Hematologic Oncology

2017 - Present

American Society of Hematology

2016 - Present

College of American Pathologists

2011 - Present

American Society of Clinical Pathology

2007 - Present

United States & Canadian Academy of Pathology

2007 - Present

College of American Pathologists

2007 - Present

Selected Presentations & Talks

Local Presentations

2025. Reevaluating constantly evolving CML risk stratification: What we're still getting wrong in 2025?. Pathology Grand Rounds. Houston, TX, US.
2018. Cytogenetic alterations in CML: old wine in old bottle. Pathology and Laboratory Medicine Grand Rounds. Houston, Texas, US.
2011. Lymphadenopathic mastocytosis. Conference. 2nd Annual Meeting for the Alumni and Friends of the Department of Hematopathology: Diagnostic Challenges and Updates in Hematopathology. Houston, Texas, US.
2011. Double-hit lymphoma. Conference. 2nd Annual Meeting for the Alumni and Friends of the Department of Hematopathology: Diagnostic Challenges and Updates in Hematopathology. Houston, Texas, US.

Regional Presentations

2018. Lymphoma diagnosis made simple: a conceptual review for surgical pathologists (2). Invited. Houston, TX, US.
2018. Lymphoma diagnosis made simple: a conceptual review for surgical pathologists (1). Invited. Houston, TX, US.

National Presentations

2024. Lymphoma diagnostics: practical insights and strategies for general pathologists (Virtual). Invited. Toledo, OH, US.
2024. Cell of origin in the diagnosis of B-cell lymphomas (Virtual). Invited. Philadelphia, PA, US.
2023. Cell of origin in the diagnosis of B-cell lymphomas (Virtual). Invited. Toledo, OH, US.
2022. Cytogenetic alterations in CML: old wine in an old bottle (Virtual). Invited. Winship Elkin Lecture. Atlanta, GA, US.
2022. Cell of origin of B-cell lymphomas: can we finally have all ducks in a row? (Virtual). Invited. Galveston, TX, US.
2021. Lymphoma diagnostics: key insights and practical strategies (Virtual). Invited. Portland, OR, US.
2021. Cell of origin of B-cell lymphomas: can we finally have all ducks in a row? (Virtual). Invited. Portland, OR, US.
2019. Lymphoma diagnostics: key insights and practical strategies. Invited. Temple, TX, US.
2019. Cytogenetic alterations in CML: old wine in an old bottle. Invited. Birmingham, AL, US.
2019. Cytogenetic alterations in CML: old wine in an old bottle. Invited. Baffalo, NY, US.
2018. Lymphoma diagnosis made simple: a conceptual review for surgical pathologists. Invited. Providence, RI, US.
2018. Lymphoma diagnosis made simple: a conceptual review for surgical pathologists. Invited. Temple, TX, US.
2017. Lymphoma diagnosis made simple: a conceptual review for surgical pathologists. Invited. Hartford, CT, US.

International Presentations

2025. Tracing the Roots: A Brief Revisit of the Cell of Origin in B-cell Lymphoma Diagnosis. Invited. NexGen Blood Cancer Forum (Virtual), US.
2025. Bridging the Gaps in CML Diagnosis: What’s Missing in Every Classifications, Guideline, and Textbook? (Virtual). Invited. Distributed Academic Halfday for the Canada-Wide Hematopathology Society. Toronto, CA.
2025. Reevaluating the Constantly Evolving CML Risk Stratification: What We’re Still Getting Wrong in 2025? (Virtual). Invited. Distributed Academic Halfday for the Canada-Wide Hematopathology Society. Toronto, CA.
2024. Small B-cell lymphomas: practical diagnostic insights and approaches for general pathologists (Virtual). Invited. Chinese American Pathologist Association-Zhejiang University Joint Lymphoma Symposium. Hangzhou.
2022. Lymphoma diagnosis made easier: roles of peripheral blood and bone marrow in lymphoma diagnosis (Virtual). Invited. Annual Meeting of Chinese Society of Clinical Oncology. Jinan, US.
2022. Evolving classification of B-cell lymphomas in WHO: past, present, and future (Virtual). Invited. Annual Jinlin International Lymphoma Symposium. Nanjing, US.
2021. Cell of origin of B-cell lymphomas: the many faces of high-grade B-cell lymphoma (Virtual). Invited. Annual Lymphoma Symposium of National Cancer Center. Beijing, CN.
2021. Cell of origin of B-cell lymphomas: can we finally have all ducks in a row? (Virtual). Invited. Inaugural Lecture of Quarterly Seminar Series, Chinese Society of Hematopathology. Nanjing, US.
2019. Lymphoma diagnosis made simple: a conceptual review beyond WHO classification. Invited. 4th Huaihai Tri-State Annual Pathology Meeting. Xuzhou, CN.
2019. Cytogenetic alterations in CML: old wine in an old bottle. Invited. Shenyang, CN.
2019. Cytogenetic alterations in CML: old wine in an old bottle. Invited. Nanjing, CN.
2019. Cytogenetic alterations in CML: old wine in an old bottle. Invited. Xuzhou, CN.
2017. Cytogenetics landscape and impact in blast phase of chronic myeloid leukemia. Invited. 11th International Conference on Hematology and Hematological Oncology. Las Vegas, US.
2017. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia treated with tyrosine kinase inhibitors. Invited. 11th International Conference on Hematology and Hematological Oncology. Las Vegas, US.

Less

Grant & Contract Support

Date:	2020 - 2022
Title:	Determination of target antigen expression (CD70) in acute myeloid leukemia and myelodysplastic syndrome
Funding Source:	Seattle Genetics
Role:	Co-I

Date:	2019 - 2021
Title:	Study of expression of SLC1A5 in leukemia
Funding Source:	MedImmune, LLC/AstraZeneca
Role:	Co-PI

Date:	2013 - Present
Title:	CD30 as a Prognostic and Therapeutic Marker in Diffuse Large B-cell lymphoma
Funding Source:	MD Anderson Cancer Center
Role:	PI
ID:	Faculty Start-Up Fund

Date:	2012 - 2013
Title:	CD30 and EBV infection in diffuse large B-cell lymphoma
Funding Source:	Department of Pathology and Lab Medicine
Role:	Trainee
ID:	Pathology Research Fellowship Award

Date:	2012 - 2013
Title:	Circulating microRNAs in myelodysplastic syndrome
Funding Source:	Department of Pathology and Lab Medicine
Role:	Trainee
ID:	Pathology Research Fellowship Award

Selected Publications

Peer-Reviewed Articles

Hu AY, Wang X, Jorgensen J, Nagarajan P, Leventaki V, Hu S, Torres-Cabala CA. Disseminated cutaneous NPM1-mutated myeloid sarcoma/ leukemia cutis mimics blastic plasmacytoid dendritic cell neoplasm and heralds bone marrow acute myeloid leukemia. Am J Dermatopathol 48(3):221-225, 2026. e-Pub 2026. PMID: 41468560.
Wei Q, Pemmaraju N, Wang SA, Hu S, DiNardo C, Issa GC, Bueso-Ramos CE, Xu J, Li S, Medeiros JL, Tang G. AML with t(10;17)(p15;q21)/ZMYND11::MBTD1: a distinct subtype characterized by minimal differentiation, CD7/CD56 expression, and poor clinical outcomes. Haematologica 111(3):1130-1135, 2026. e-Pub 2026. PMID: 41262054.
Wang WJ, Hu Z, Gehris BT, Naik U, Bhattacharjee MB, Wahed MA, Hu S, You MJ, Chen L, Wang W, Medeiros LJ. Clinicopathological features of primary epidural B-cell lymphoma: a study of 14 cases. Pathology 58(1):24-29, 2026. e-Pub 2026. PMID: 41062339.
Wang WJ, Wang SA, Fang H, Jorgensen JL, Hu S, Qiu L, Xu J, Medeiros LJ, Wang W. Mature T-cell leukemia/lymphoma with an NK-like immunophenotype: A report of 7 cases. Cytometry B Clin Cytom. e-Pub 2026.
Wang WJ, Wang SA, Fang H, Wei Q, Hu S, Loghavi S, Al-Atrash G, Zang C, Wei P, Medeiros LJ, Wang W. Monitoring relapse in post-transplant acute myeloid leukemia requires integrated assessment, with flow cytometry showing highest efficacy. Haematologica. e-Pub 2026.
Wang X, Tang G, Hu, Z, Medeiros LJ, Hu S. Splenic B-cell lymphoma/leukemia with TCL1 gene rearrangement. Int J Lab Hematol. e-Pub 2026.
Wang WJ, Wang SA, Al-Atrash G, Fang H, Hu S, Li S, Xu J, Wei Q, Medeiros LJ, Wang W. T-cell mixed chimerism after allogeneic hematopoietic stem cell transplantation does not correlate with relapse in patients with acute myeloid leukemia. Leuk Res. e-Pub 2026.
Tang G, Wang SA, Jen WY, Medeiros LJ, Wang W, Fang H, Hu S, Jain N, Jabour E, Zou Y, Xu J. Acute leukemia with BCL11B rearrangements: genetic landscape, BCL11B expression, and therapeutic response. Human Pathol. e-Pub 2026. PMID: 41581705.
Wang WJ, Shen Q, Tashakori M, Fang H, Shuai W, Lin P, Zhang Z, Tang G, Wang W, Linden ML, Jabbour EJ, Kadia TM, Short NJ, Daver NG, Medeiros LJ, Hu S. Mixed-phenotype acute leukemia with mutated TP53: genetic landscape, therapeutic response, and outcomes. Am J Hematol 101(1):133-137, 2026. e-Pub 2026. PMID: 41195731.
Chen M, Tang G, Hu S. Persistent monosomy 7 in Philadelphia chromosome-negative cells without disease progression over nearly two decades of follow-up in chronic myeloid leukemia. Cancer Genet. e-Pub 2026. PMID: 41579782.
Wang WJ, Hu S. CML-like biology is a unifying feature of myeloid/lymphoid neoplasms with tyrosine kinase fusions in lymphoid blast phase. Comment on: Multilineage involvement in ABL-class fusion–positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology. Haematologica. e-Pub 2026.
Wang WJ, Wang SA, Fang H, Wei Q, Jorgensen J, Hu S, Xu J, Li S, Tang G, Tang Z, Medeiros LJ, Wang W. Challenges and approaches in the diagnosis and differential diagnosis of atypical CLL: a response to ‘Defining Atypical CLL for Reproducible Diagnosis: Implications of the Work by Wang et a’. Cytometry B Clin Cytom. e-Pub 2025. PMID: 41406113.
Hu S, Tang G. Mantle cell lymphoma with KMT2A rearrangement. Blood 146(20):2491, 2025. e-Pub 2025. PMID: 41231456.
Wei Q, Wang SA, Garcia-Manero G, Kanagal-Shamanna R, Toruner GA, Hu S, Loghavi S, OK CY, Medeiros LJ, Tang G. Optical genome mapping in myelodysplastic syndromes: Clinical value and limitations derived from a cohort of 236 patients. Mod Pathol 38(10):100862, 2025. e-Pub 2025. PMID: 40780682.
Medeiros LJ, Zhou J, Wang X, Wang W, Tang G, Hu S. Leukemic phase of MYC/BCL2 double-hit high-grade B-cell lymphoma: a report of 35 cases. Hum Pathol 164:105933, 2025. e-Pub 2025. PMID: 40925489.
Ok, CY, Tang, G, Loghavi, S, Hu, S, Wei, Q, Quesada, AE, Routbort, MJ, Kanagal Shamanna, R, Yin, CC, Sarami, I, Garces, S, Agarwal, N, Luthra, R, Fang, H, Jelloul, FZ, Bryan, J, Medeiros, LJ, Patel, KP, Toruner, GA. Comparative analysis of targeted RNA-Seq and optical genome mapping for detecting gene rearrangements in acute leukemia. Cancers 17(21):3458, 2025. e-Pub 2025. PMID: 41228256.
E S, Vega F, Khanlari M, Fang H, Xu J, Li S, Hu S, Wang SA, Wei Q, Wang WJ, Medeiros LJ, Wang W. BCL11B helps to define T-lineage in lymphomas/leukemias with a mixed/ambiguous immunophenotype. Pathology 57(6):746-752, 2025. e-Pub 2025. PMID: 40318959.
Ok CY, Tang G, Loghavi S, Hu S, Wei Q, Quesada AE, Routbort MJ, Kanagal-Shamanna R, Yin CY, Sarami I, Garces S, Agarwal NK, Luthra R, Fang H, Jelloul FZ, Iorgulescu B, Medeiros LJ, Patel KP, Toruner GA. Comparative analysis of targeted RNA-Seq and optical genome mapping for detecting gene rearrangements in acute leukemia. Cancers (Basel) 17(21):3458, 2025. e-Pub 2025. PMID: 41228256.
Azevedo RS, Fayad L, Shamanna RK, Loghavi S, Hu S, Bueso-Ramos CE, Sasaki K, Abuasab T, Khawaja F, Goulart H, Abou Dalle I, Borthakur G, Pemmaraju N. Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation. Leuk Lymphoma 66(10):1947-1951, 2025. e-Pub 2025. PMID: 40440732.
Wang WJ, Wang SA, Fang H, Wei Q, Jorgensen J, Hu S, Xu J, Li S, Tang G, Tang Z, Medeiros LJ, Wang W. Immunophenotypic, cytogenetic, and mutational features of chronic lymphocytic leukemia/small lymphocytic lymphoma with atypical immunophenotype. Cytometry B Clin Cytom. e-Pub 2025. PMID: 40814768.
Shen Q, Haddad FG, Jabbour EJ, Tang G, Fang H, Liu M, Hu AY, Wang W, Lin P, Issa GC, Kantarjian HM, Medeiros LJ, Hu S. Unusually indolent CML: absence of complete cytogenetic response after 10 years of tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk 25(8):e580-e590, 2025. e-Pub 2025. PMID: 40345959.
Wang SA, Li S, Wang W, Xu J, Thakral B, Hu S, Ok CY, Jia F, Jorgensen J, Medeiros LJ, Ravandi-Kashani F, Short NJ, Loghavi S. Technical and clinical validity of assessing measurable residual disease by multicolor flow cytometry in an unselected acute myeloid leukemia patient cohort. Arch Pathol Lab Med 150(1):72-80, 2025. e-Pub 2025. PMID: 40522873.
Shen Q, Tang G, Haddad FG, Chen W, Wang WJ, Wang W, Medeiros LJ, Hu S. Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy. Leuk Lymphoma 66(5):977-980, 2025. e-Pub 2025. PMID: 39801075.
Tang G, Jain P, Hu S, Ok CY, Wang WJ, Quesada AE, Wei Q, Li S, Xu J, Loghavi S, Toruner GA, L Medeiros LJ. Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1. Hum Pathol, 2025. e-Pub 2025. PMID: 40381701.
Haddad F, Sasaki K, Senapati J, Hu S, Dellasala S, Issa GC, Jabbour E, Kantarjian HM. Successful treatment-free remission after ponatinib discontinuation in pretreated patients with chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk 25(4):254-257, 2025. e-Pub 2025. PMID: 39592322.
Toruner GA, Hu S, Loghavi S, OK CY, Tang Z, Wei Q, Kanagal-Shamanna R, Medeiros LJ, Tang G. Clinical utility of optical genome mapping as an additional tool in a standard cytogenetic workup in hematological malignancies. Cancers (Basel) 17(9):1436, 2025. e-Pub 2025. PMID: 40361363.
Wei Q, Hu S, Loghavi S, Toruner GA, Ravandi F, Tang Z, Li S, Xu J, Daver N, Medeiros LJ, Tang G. Chromoanagenesis is frequently associated with highly complex karyotypes, extensive clonal heterogeneity, and treatment refractoriness in acute myeloid leukemia. Am J Hematol 100(3):417-4267, 2025. e-Pub 2025. PMID: 39871121.
Shen Q, Hu S. Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements. Blood 145(6):652, 2025. e-Pub 2025. PMID: 39913335.
Dimopoulos Y, Wang W, Wang SA, Loghavi S, DiNardo C, Gerstein YS, Hu S, Tang Z, Ilagan C, Thakral B, El Hussein S, Xu J, Li S, Lin P, Patel KP Ok CY, Medeiros LJ, Fang H. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol 99(12):2416-2419, 2024. e-Pub 2024. PMID: 39392132.
Fang H, Wang SA, Beird HC, Tang Z, You MJ, Li S, Xu J, Hu S, Yin CC, El Hussein S, Lin P, Jelloul FZ, Vega F, Medeiros LJ, Wang W. Morphology, immunophenotype, and suggested diagnostic criteria of TCL1-family negative T-prolymphocytic leukemia. Am J Clin Pathol 162(6):582-590, 2024. e-Pub 2024. PMID: 38946194.
Wei Q, Hu S, Xu J, Loghavi S, Daver N, Toruner G, Wang W, Medeiros LJ, Tang G. Detection of KMT2A partial tandem duplication by optical genome mapping in myeloid neoplasms: associated cytogenetics, gene mutations, treatment responses, and patient outcomes. Cancers (Basel) 16(24):4193, 2024. e-Pub 2024. PMID: 39766092.
Shen Q, Jabbour EJ, Tang G, Fang H, Wang W, Short NJ, You MJ, Medeiros LJ, Hu S. Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia. Am J Hematol 99(11):2244-2248, 2024. e-Pub 2024. PMID: 39152741.
Sameeta, Wang SA, Tang Z, Khoury JD, Fang F, Wang D, Xu J, Li S, Hu Z, Hu S, Jorgensen JL, Medeiros LJ, Wang W. Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. Am J Clin Pathol 162(5):455-463, 2024. e-Pub 2024. PMID: 38801226.
Pattali S, Hu S, Bashir Q, Champlin RE, Qazibash MH. The synchronous diagnosis of multiple myeloma (MM) and chronic myeloid leukemia (CML). Cureus 16(11):e73583, 2024. e-Pub 2024. PMID: 39677110.
Loghavi S, Wei Q, Ravandi F, Quesada AE, Routbort MJ, Hu S, Toruner GA, Wang SA, Wang W, Miranda RN, Li S, Xu J, DiNardo CD, Daver N, Kadia TM, Issa GC, Kantarjian HM, Medeiros LJ, Tang G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol 99(10):1959-1968, 2024. e-Pub 2024. PMID: 39016111.
Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad F, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of MECOM rearrangements in chronic myeloid leukemia. Int J Hematol 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
Dong Q, Wang Y, Xiu Y, Wu X, O’Neill S, Meyerson H, Tobias S, Moriggl R, Hu S, Wang W, Zhao C. Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML. Br J Haematol 204(6):2487-2491, 2024. e-Pub 2024. PMID: 38508872.
Hu S, Jabbour EJ, Hu CY, Tang G, Wang W, Medeiros LJ, Bueso-Ramos C. Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive? B-ALL and pose a diagnostic challenge. Am J Hematol 99(4):721-726, 2024. e-Pub 2024. PMID: 38240333.
Quesada AE, Hu S, Li S, Toruner GA, Wei Q, Loghavi S, Ok CY, Jain P, Thakral B, Nwogbo OV, Kim D, Iyer SP, You MJ, Medeiros LJ, Tang G. Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma. Hum Pathol 144:71-76, 2024. e-Pub 2024. PMID: 38301962.
Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, Hu AY, E S, Liu M, Fang H, Wang W, Tang G, Apperley JF, Hochhaus A, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S. Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis: A report from the BCR::ABL1 Pathology Group. Mod Pathol 37(2):100406, 2024. e-Pub 2024. PMID: 38104892.
Zhou T, Curry CV, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, Xie W, Jelloul FZ, King RL, Yuan J, Wang X, Zhao C, Obiorah IE, Courville EL, Nomura E, Cherian S, Xu ML, Burack WR, Liu HX, Jabbour EJ, Takahashi K, Wang W, Wang SA, Khoury JD, Medeiros LJ, Hu S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J 14(1):19, 2024. e-Pub 2024. PMID: 38272888.
Jiang C, Huang LY, Zhou JH, Li ZM, Wang Y, Li S, Fu JC, Huang QT, Yan Q, Huang YY, Zuo M, Hu S, Gale RP, Liang Y, Yun JP, Huang YH. Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma. iScience 27(1):108630, 2024. e-Pub 2024. PMID: 38188529.
Tang G, Wu Y, Lin P, Toruner GA, Hu S, Li S, Qazilbash MH, Orlowski RZ, Ye C, Xu J, Nahmod KA, Medeiros LJ, Tang Z. Cytogenetic profile in monoclonal gammopathy of undetermined significance, smoldering and symptomatic multiple myeloma: A study of 1087 patients with highly purified plasma cells. Cancers (Basel) 15(23), 2023. e-Pub 2023. PMID: 38067393.
Yuan J, Liu H, Hu S, Miranda RN, Xu X, Bayerl MG, Artymiuk CJ, Berg H, King RL, Shi M, He R, Viswanatha D, Medeiros LJ, McPhail ED. Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients. Hum Pathol 141:22-29, 2023. e-Pub 2023. PMID: 37634651.
Wang SA, Jorgensen JL, Hu S, Jia F, Li S, Loghavi S, Ok CY, Thakral B, Xu J, Medeiros LJ, Wang W. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom 104(5):356-366, 2023. e-Pub 2023. PMID: 37605812.
Fang H, Beird HC, Wang SA, Ibrahim A, Tang Z, Tang G, You MJ, Hu S, Xu J, Li S, Yin CC, El Hussein S, Le N, Futreal PA, Bueso-Ramos C, Thakral B, Kadia T, Thornton R, Little L, Gumbs C, Song X, Medeiros LJ, Wang W. T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis. Leukemia 37(9):1919-1921, 2023. e-Pub 2023. PMID: 37443196.
Xiang C, Wu W, Fan M, Wang Z, Feng X, Liu C, Liu J, Liu G, Xia L, Si H, Gu Y, Liu N, Luo D, Wang Y, Ma D, Hu S, Liu H. Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS. Front Immunol 14:1132834, 2023. e-Pub 2023. PMID: 37388733.
Yang Y, Tang Z, Huang Y, Hu Q, Wang S, Ji J, Du Y, Yang C, Chen M, Hu S, Han B. Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study. Blood Cancer J 13(1):74, 2023. e-Pub 2023. PMID: 37160872.
Al-Jumaili Z, Zhang YH, Wang WJ, Mai B, Wang XI, Ahmed A, Wang W, Hu S, You MJ, Hu Z. High-grade B-cell lymphoma with malignant effusions as the initial presentation. Am J Clin Pathol 159(5):420-428, 2023. e-Pub 2023. PMID: 36879405.
Tang G, Li S, Toruner GA, Jain P, Tang Z, Hu S, Xu J, Cheng J, Robinson M, Vega F, Medeiros LJ. Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas. Cancer Genet 272-273:1-8, 2023. e-Pub 2023. PMID: 36566629.
Hu Z, Medeiros LJ, Xu M, Yuan J, Peker D, Shao L, Tang Z, Mai B, Thakral B, Rio A, Hu S, Wang W. T-cell prolymphocytic leukemia with t(X;14)(q28;q11.2): a clinicopathologic study of 15 cases. Am J Clin Pathol 159(4):325-336, 2023. e-Pub 2023. PMID: 36883805.
Dong Q, Wang Y, Xiu Y, Sakr H, Burnworth B, Xu D, O'Brien T, Burke J, Hu S, Zeng G, Zhao C. Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma. Br J Haematol 200(5):660-664, 2023. e-Pub 2023. PMID: 36375473.
Fang H, Khoury JD, Torres-Cabala CA, Ng SB, Xu J, El Hussein S, Hu S, Vega F, Li S, Tang Z, Tang G, Medeiros LJ, Wang W. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Pathology 54(7):893-899, 2022. e-Pub 2022. PMID: 35864006.
Wang WJ, Gehris BT, Mai B, Chen L, Hu S, You MJ, Hu Z. HHV8-negative effusion-based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation. Leuk Lymphoma 63(14):3480-3483, 2022. e-Pub 2022. PMID: 36154351.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
Fang H, Wang SA, You MJ, Hu S, Miranda RN, Tang Z, Lin P, Jorgensen JL, Xu J, Thakral B, Schlette EJ, EI Hussein S, Bueso-Ramos C, Medeiros LJ, Wang W. Flow cytometry immunophenotypic features of pure erythroid leukemia and its distinction from reactive erythroid precursors. Cytometry B Clin Cytom 102(6):440-447, 2022. e-Pub 2022. PMID: 36156384.
Yu F, He H, Nastoupil LJ, Xu-Monette ZY, Pham K, Liang Y, Chen G, Fowler NH, Yin CC, Tan D, Yang Y, Hu S, Young KH, Pham LV, You MJ. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Am J Cancer Res 12(10):4666-4679, 2022. e-Pub 2022. PMID: 36381323.
Xie W, Raess PW, Dunlap J, Hoyos CM, Li H, Li P, Swords R, Olson SB, Yang F, Anekpuritanang T, Hu S, Wiszniewska J, Fan G, Press RD, Moore SR. Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome. Leuk Lymphoma 63(8):1907-1916, 2022. e-Pub 2022. PMID: 35258401.
Wang X, Tang G, Hu Z, Fang H, Wang W, Tang Z, Toruner GA, Zhou T, DiNardo CD, Garcia-Manero G, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Hu S. Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival. Br J Haematol 198(3):604-608, 2022. e-Pub 2022. PMID: 35645146.
Fang H, Wang SA, Hu S, Konoplev SN, Mo H, Liu W, Zuo Z, Xu J, Jorgensen JL, Yin CC, El Hussein S, Jelloul FZ, Tang Z, Medeiros LJ, Wang W. Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom 102(4):283-291, 2022. e-Pub 2022. PMID: 35716019.
Wang W, Xu J, Khoury JD, Pemmaraju N, Fang H, Miranda RN, Yin CC, Hussein SE, Jia F, Tang Z, Hu S, Konopleva M, Medeiros LJ, Wang SA. Immunophenotypic and molecular features of acute myeloid leukemia with plasmacytoid dendritic cell differentiation are distinct from blastic plasmacytoid dendritic cell neoplasm. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884435.
Huang Y, Hu S, Larson DP, Shi M, He R, Dave BJ, Greiner TC, Fu K, McPhail ED, Ketterling RP, Medeiros LJ, Yuan J. Composite classic Hodgkin lymphoma and follicular lymphoma: A clinicopathologic study of 22 cases with review of 27 additional cases in the literature. Am J Surg Pathol 46(6):793-800, 2022. e-Pub 2022. PMID: 35067515.
Zhao M, Medeiros LJ, Wang W, Tang G, Jung HS, Sfamenos SM, Fang H, Toruner GA, Hu S, Yin CC, Lin P, Gu J, Peng G, You MJ, Khoury JD, Wang SA, Tang Z. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet 262-263:23-29, 2022. e-Pub 2022. PMID: 34974290.
Tang G, Zou Y, Wang SA, Borthakur G, Toruner G, Hu S, Li S, Xu J, Medeiros LJ, Tang Z. 3’ CBF deletion in CFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. Ann Hematol 101(4):847-854, 2022. e-Pub 2022. PMID: 35184217.
Ghosh A, Chen L, Wahed A, Wang W, Saluja K, Nguyen AND, Hu S, Hu Z. Incidental but rapidly progressing T-cell prolymphocytic leukemia with t(X;14)(q28;q11) involving parotid lymphoepithelial cysts: A diagnostic pitfall. Int J Lab Hematol 44(1):e17-e20, 2022. e-Pub 2022. PMID: 34275205.
Liu H, Xu-Monette ZY, Tang G, Wang W, Kim Y, Yuan J, Li Y, Chen W, Li Y, Fedoriw GY, Zhu F, Fang X, Luedke C, Medeiros LJ, Young KH, Hu S. EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology 80(3):575-588, 2022. e-Pub 2022. PMID: 34637146.
Ricks E, Hu S, Hu Z. Cytokeratin-positive follicular dendritic cell sarcoma: a mimic of carcinoma. EJHaem 3(1):254-255, 2022. e-Pub 2022. PMID: 35846219.
El Hussein S, Hu S, Fang H, Garces S, Muzzafar T, Wang SA, Medeiros LJ, Bueso-Ramos C, Jelloul FZ. Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity. Leuk Lymphoma 63(1):235-238, 2022. e-Pub 2022. PMID: 34510998.
Liu H, Hu S. EBV+ ALK+ large B-cell lymphoma. Blood 138(25):2741, 2021. e-Pub 2021. PMID: 34940813.
Young PE, Kanagal-Shamanna R, Hu S, Tang G, Thakral B, Daver N, Issa GC, Medeiros LJ, Konoplev S. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. Leuk Res 111:106685, 2021. e-Pub 2021. PMID: 34438119.
Liu H, Shen Q, Chang CC, Hu S. Phenotypic switch in high-grade B-cell lymphoma with MYC and BCL6 rearrangements: A potential mechanism of therapeutic resistance in lymphoma?. Front Oncol 11:795330, 2021. e-Pub 2021. PMID: 35004320.
Sui J, Kelmenson D, Hu S, Cao L. Acute respiratory distress syndrome in a patient with acute promyelocytic leukemia: Overlapping between differentiation syndrome and COVID-19. J Hematol 10(5):217-220, 2021. e-Pub 2021. PMID: 34804311.
Yin W, Cheng J, Tang Z, Toruner G, Hu S, Guo M, Robinson M, Medeiros LJ, Tang G. MET amplification (MET/CEP7 ratio = 1.8) is an independent poor prognostic marker in patients with treatment-naive non-small-cell lung cancer. Clin Lung Cancer 22(4):e512-e518, 2021. e-Pub 2021. PMID: 33288441.
Fang H, Wang SA, Xie W, Tang Z, Hu S, Krishnamurthy S, Medeiros LJ, Wang W. Clinicopathologic features of myelodysplastic syndromes involving lymph nodes. Am J Surg Pathol 45(7):930-938, 2021. e-Pub 2021. PMID: 33739784.
Fang H, Yabe M, Zhang X, Kim Y, Wu X, Wei P, Chi S, Zheng L, Garcia-Manero G, Shao L, Yuan J, Shen Y, Zheng G, Tang G, Wang W, Loghavi S, Shen Q, Yuan Y, He R, Chen D, Medeiros LJ, Hu S. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol 34(6):1143-1152, 2021. e-Pub 2021. PMID: 33558656.
Hu Z, Singhi EK, Apostolidou E, Mai B, Juneja HS, Hu S. Mass-forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia. Int J Lab Hematol 43(3):e135-e137, 2021. e-Pub 2021. PMID: 33314782.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Chen F, Hu S, Ruan J, Chen M, Han B. Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. Blood Cancer J 11(3):58, 2021. e-Pub 2021. PMID: 33727526.
Ronaghy A, Hu S, Tang Z, Wang W, Tang G, Loghavi S, Li S, Thakral B, Medeiros LJ, Muzzafar T. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol 34(2):300-313, 2021. e-Pub 2021. PMID: 33110238.
Fang H, Chuang HH, Strati P, Hu S, Shuai W, Medeiros LJ, Wang W. Postchemotherapy histiocyte-rich pseudotumor mimicking residual lymphoma: a report of 11 cases correlating clinicopathologic and radiologic findings. Am J Surg Pathol 45(2):160-168, 2021. e-Pub 2021. PMID: 32769427.
Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Medeiros LJ, Lin P. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol 34(2):327-335, 2021. e-Pub 2021. PMID: 32908255.
Hu Z, Pan Z, Chen W, Shi Y, Wang W, Yuan J, Wang E, Zhang S, Kurt H, Mai B, Zhang X, Liu H, Rios AA, Ma HY, Nguyen ND, Medeiros LJ, Hu S. Primary effusion lymphoma: A clinicopathological study of 70 cases. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33669719.
Yin W, Liu W, Guo M, Tang Z, Toruner G, Robinson M, Cheng J, Hu S, Medeiros LJ, Tang G. Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patient outcome. Exp Mol Pathol 118:104572, 2021. e-Pub 2021. PMID: 33189723.
Chen Z, Hu S, Wang SA, Konopleva M, Tang Z, Xu J, Li S, Toruner G, Thakral B, Medeiros LJ, Tang G. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia chromosome-positive B-lymphoblastic leukemia. Leuk Lymphoma 61(12):2831-2838, 2020. e-Pub 2020. PMID: 32700989.
Li K, Xu W, Lu K, Wen Y, Xin T, Shen Y, Lv X, Hu S, Jin R, Wu X. CSF-1R inhibition disrupts the dialog between leukaemia cells and macrophages and delays leukaemia progression. J Cell Mol Med 24(22):13115-13128, 2020. e-Pub 2020. PMID: 33037771.
Mai B, Wang W, Lin M, Hu S, Wang XI, Chen L, Wahed A, Nguyen A, Ma HY, Medeiros LJ, Hu Z. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients. AIDS 34(12):1735-1743, 2020. e-Pub 2020. PMID: 32889849.
Tang Z, Toruner GA, Tang G, Cameron Yin C, Wang W, Hu S, Thakral B, Wang SA, Miranda RN, Khoury JD, Medeiros LJ. Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. Mod Pathol 33(10):2035-2045, 2020. e-Pub 2020. PMID: 32404952.
Liu H, Miao Y, Ferrajoli A, Tang G, McDonnell T, Medeiros LJ, Hu S. Leukemic phase of Richter transformation: a mimic of acute myeloid leukemia that responded to ibrutinib monotherapy. Am J Hematol 95(10):1221-1223, 2020. e-Pub 2020. PMID: 32162729.
Wang W, Beird H, Kroll CJ, Hu S, Bueso-Ramos CE, Fang H, Tang G, Tang Z, Wang F, Takahashi K, You MJ, Khoury JD, Medeiros LJ, Futreal PA. T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. Leukemia 34(9):2509-2512, 2020. e-Pub 2020. PMID: 32099038.
Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, Wei P, Khoury JD, You MJ, Loghavi S, Tang Z, Fang H, Thakral B, Medeiros LJ, Wang W. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J 10(8):86, 2020. e-Pub 2020. PMID: 32848129.
Wang Z, Gong Q, Zhao Y, Xu H, Hu S, Zhang Z. Indolent EBV-positive T-cell lymphoproliferative disorder arising in a chronic pericardial hematoma: the T-cell counterpart of fibrin-associated diffuse large B-cell lymphoma?. Haematologica 105(8):e437-e439, 2020. e-Pub 2020. PMID: 32414846.
Xie W, Xu J, Hu S, Li S, Wang W, Cameron Yin C, Toruner G, Tang Z, Jeffrey Medeiros L, Tang G. iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. Mod Pathol 33(7):1389-1397, 2020. e-Pub 2020. PMID: 32034282.
Gong Z, Zhou T, Liu H, Tang G, Yin CC, Wang W, Medeiros LJ, Hu S. Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. Br J Haematol 189(5):e207-e211, 2020. e-Pub 2020. PMID: 32237084.
Liu H, Xiang C, Wu M, Hu S. Follicular dendritic cell sarcoma with co-expression of CD4 and CD30 mimics anaplastic large cell lymphoma. Front Oncol 10:876, 2020. e-Pub 2020. PMID: 32547956.
Liu H, Hu S. Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation. Blood 135(17):1506, 2020. e-Pub 2020. PMID: 32324873.
Shen J, Medeiros LJ, Li S, Wang SA, Lin P, Khanlari M, Iyer SP, Yin CC, Tang G, Jorgensen JL, Hu S, Miranda RN, Xu J. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Hum Pathol 98:1-9, 2020. e-Pub 2020. PMID: 32032618.
Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen Q, Zhou Y, Garcia-Manero G, Loghavi S, Hu AY, Wang S, Bueso-Ramos CE, Kantarjian HM, Medeiros LJ, Hu S. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. Ann Hematol 99(3):487-500, 2020. e-Pub 2020. PMID: 32006151.
Toruner GA, Tang Z, Tang G, Medeiros LJ, Hu S. Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. Cancer Genet 241:57-60, 2020. e-Pub 2020. PMID: 31870845.
Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol 95(2):227-229, 2020. e-Pub 2020. PMID: 31400013.
Xiu Y, Dong Q, Fu L, Bossler A, Tang X, Boyce B, Borcherding N, Leidinger M, Sardina JL, Xue HH, Li Q, Feldman A, Aifantis I, Boccalatte F, Wang L, Jin M, Khoury J, Wang W, Hu S, Yuan Y, Wang E, Yuan J, Janz S, Colgan J, Habelhah H, Waldschmidt T, Müschen M, Bagg A, Darbro B, Zhao C. Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. Blood 135(2):108-120, 2020. e-Pub 2020. PMID: 31697816.
Xie W, Chen Z, Wang SA, Hu S, Li S, Miranda RN, Medeiros LJ, Tang G. Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Leuk Lymphoma 60(12):2993-3001, 2019. e-Pub 2019. PMID: 31017498.
Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol 94(10):E256-E259, 2019. e-Pub 2019. PMID: 31273842.
Chen Z, Sun Y, Xie W, Wang SA, Hu S, Li S, Tang Z, Toruner G, Medeiros LJ, Tang G. Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?. Cancer Med 8(9):4093-4099, 2019. e-Pub 2019. PMID: 31173486.
Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42, 2019. e-Pub 2019. PMID: 31132650.
Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros L. Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data Brief 24:104025, 2019. e-Pub 2019. PMID: 31193989.
Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. Ann Hematol 98(5):1149-1157, 2019. e-Pub 2019. PMID: 30759270.
Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet 233-234:21-31, 2019. e-Pub 2019. PMID: 31109591.
Hu Z, Ramos CEB, Medeiros LJ, Zhao C, Yin CC, Li S, Hu S, Wang W, Thakral B, Xu J, Verstovsek S, Lin P. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. Hum Pathol 85:290-298, 2019. e-Pub 2019. PMID: 30447300.
Tang G, Hu S, Wang SA, Xie W, Lin P, Xu J, Toruner G, Zhao M, Gu J, Doty M, Li S, Medeiros LJ, Tang Z. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J Mol Diagn 21(2):343-351, 2019. e-Pub 2019. PMID: 30576868.
Xie W, Wang SA, Hu S, Xu J, Medeiros LJ, Tang G. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. Cancer Genet 228-229:41-46, 2018. e-Pub 2018. PMID: 30553471.
Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL, d'Orcy E, Yin CC, Cortes J, Jabbour EJ, Kantarjian HM, Bueso-Ramos CE. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer 124(19):3849-3855, 2018. e-Pub 2018. PMID: 30321462.
Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP, Hu S, Lu X, Toruner GA, Medeiros LJ, Khoury JD. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res 73:86-94, 2018. e-Pub 2018. PMID: 30248580.
Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 7:26, 2018. e-Pub 2018. PMID: 30323983.
Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. e-Pub 2018. PMID: 30054307.
Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu S. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol 31(7):1141-1154, 2018. e-Pub 2018. PMID: 29449681.
Boddu PC, Wang S, Pemmaraju N, Tang Z, Hu S, Li S, Xu J, Medeiros LJ, Tang G. 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leuk Res 66:73-78, 2018. e-Pub 2018. PMID: 29407586.
Hidalgo-Lopez JE, Carballo-Zarate A, Verstovsek S, Wang SA, Hu S, Li S, Xu J, Zuo W, Tang Z, Yin CC, Medeiros LJ, Bueso-Ramos CE, Tang G. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol 97(3):425-434, 2018. e-Pub 2018. PMID: 29285580.
Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget 9(16):12959-12970, 2018. e-Pub 2018. PMID: 29560123.
Hu Z, Hu S, Ji C, Tang Z, Thakral B, Loghavi S, Medeiros LJ, Wang W. 3q26.2/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: an early event associated with a poor prognosis. Leuk Res, 2018. e-Pub 2018. PMID: 29288910.
Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen JL, McDonnell TJ, Wang W, Kantarjian HM, Hu S. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv 1(26):2541-2552, 2017. e-Pub 2017. PMID: 29296906.
Zheng L, Hu S. Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse. Blood 130(12):1483, 2017. e-Pub 2017. PMID: 28935645.
Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 102(9):1511-1518, 2017. e-Pub 2017. PMID: 28473622.
Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9(1):346-360, 2017. e-Pub 2017. PMID: 29416618.
Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol 178(3):403-412, 2017. e-Pub 2017. PMID: 28382648.
Hu Z, Medeiros LJ, Wang W, Chen Z, Tang G, Hodjat P, Yang S, Fang L, Li Y, Verstovsek S, Hu S. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol 30(7):940-951, 2017. e-Pub 2017. PMID: 28338652.
Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian H, Hu S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J 7(7):e583, 2017. e-Pub 2017. PMID: 28708130.
Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury J. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: a series of 10 cases of a clinically aggressive neoplasm. Am J Hematol 92(6):520-528, 2017. e-Pub 2017. PMID: 28253536.
Hu Z, Medeiros LJ, Fang L, Sun Y, Tang Z, Tang G, Sun T, Quesada AE, Hu S, Wang SA, Pei L, Lu X. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol 92(5):441-447, 2017. e-Pub 2017. PMID: 28194886.
Baraban EG, Hu S, Hui P, Podoltsev N, Cooper D, Xu ML. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplant 52(4):634-637, 2017. e-Pub 2017. PMID: 27991892.
Gong Z, Xie W, Wang W, Chen Z, Xu J, Yuan J, Zhou Y, Wang D, Medeiros LJ, Hu S. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases. Int J Lab Hematol 39(2):e45-e50, 2017. e-Pub 2017. PMID: 27863007.
Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, Hu B, Oki Y, Li S. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol 98(4):415-421, 2017. e-Pub 2017. PMID: 28039906.
Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RN. Immunophenotypic shifts in primary cutaneous γδ T-cell lymphoma suggest antigenic modulation: A study of sequential biopsy specimens. Am J Surg Pathol 41(4):431-445, 2017. e-Pub 2017. PMID: 28248813.
Gur HD, Wang SA, Tang Z, Hu S, Li S, Medeiros LJ, Tang G. Clinical significance of isolated del(7p) in myeloid neoplasms. Leuk Res 55:18-22, 2017. e-Pub 2017. PMID: 28119224.
Chen Z, Shao C, Wang W, Zuo Z, Mou X, Hu SJ, DiGiuseppe JA, Zu Y, Medeiros LJ, Hu S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 31(3):585-592, 2017. e-Pub 2017. PMID: 27560111.
Gong Z, Zheng L, Tang Z, Chen Z, Wang W, Bai S, Tang G, Jeffrey Medeiros L, Hu S. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 96(3):501-504, 2017. e-Pub 2017. PMID: 27915425.
Oo TH, Hu S. Copper deficiency-related bone marrow changes secondary to long-term total parenteral nutrition. Clin Case Rep 5(2):195-196, 2017. e-Pub 2017. PMID: 28174650.
Bai S, Hu S. BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease. Br J Haematol 176(4):514, 2017. e-Pub 2017. PMID: 27982417.
Hu Z, Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, Lu X, Pham LV, Young KH, Wang W, Hu S. Mantle cell lymphoma with MYC rearrangement: A report of 17 patients. Am J Surg Pathol 41(2):216-224, 2017. e-Pub 2017. PMID: 27776009.
Chen Z, Medeiros LJ, Kantarjian HM, Zheng L, Gong Z, Patel KP, Xiong H, Wang W, Cortes JE, Hu S. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J 7(2):e521, 2017. e-Pub 2017. PMID: 28157214.
Huang L, Wang SA, DiNardo C, Li S, Hu S, Xu J, Zhou W, Goswami M, Medeiros LJ, Tang G. Tetraploidy/near-tetraploidy acute myeloid leukemia. Leuk Res 53:20-27, 2017. e-Pub 2017. PMID: 27951415.
Pan Z, Hu S, Li M, Zhou Y, Kim YS, Reddy V, Sanmann JN, Smith LM, Chen M, Gao Z, Wang HY, Yuan J. ALK-positive large B-cell lymphoma: A clinicopathologic study of 26 cases with review of additional 108 cases in the literature. Am J Surg Pathol 41(1):25-38, 2017. e-Pub 2017. PMID: 27740969.
Miao Y, Hu S, Lu X, D SL, Wang W, Medeiros LJ, Lin P. Double-hit follicular lymphoma with MYC and BCL2 translocations: A study of 7 cases with a review of literature. Hum Pathol 58:72-77, 2016. e-Pub 2016. PMID: 27544800.
Wang W, Chen Z, Hu Z, Yin CC, Li S, Bai S, Bueso-Ramos CE, Medeiros LJ, Hu S. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J 6(11):e490, 2016. e-Pub 2016. PMID: 27813536.
Tang Z, Li Y, Wang SA, Hu S, Li S, Lu X, Khoury JD, Medeiros LJ, Tang G. Clinical significance of acquired loss of the X chromosome in bone marrow. Leuk Res 47:109-13, 2016. e-Pub 2016. PMID: 27299973.
Goswami RS, Wang SA, DiNardo C, Tang Z, Li Y, Zuo W, Hu S, Li S, Medeiros LJ, Tang G. Newly emerged isolated del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Mod Pathol 29(7):727-34, 2016. e-Pub 2016. PMID: 27056073.
Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30(7):1606-1609, 2016. e-Pub 2016. PMID: 26837843.
Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127(22):2742-50, 2016. e-Pub 2016. PMID: 27006386.
Li Y, Hu S, Wang SA, Li S, Huh YO, Tang Z, Medeiros LJ, Tang G. The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. Mod Pathol 29(5):444-451, 2016. e-Pub 2016. PMID: 26916070.
Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic factors of hepatosplenic T-cell lymphoma: Clinicopathologic study of 28 cases. Am J Surg Pathol 40(5):676-88, 2016. e-Pub 2016. PMID: 26872013.
Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu, X, Yang W, Dadfarnia M, Kantarjian HM, Medeiros LJ, Hu S. Differential clinical and prognostic impact of myeloid sarcoma versus medullary myeloid blast phase in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer J 6(e418), 2016. e-Pub 2016. PMID: 27152845.
Wang W, Ali S, Tang Z, Miranda RN, Yang S, Medeiros LJ, Hu S. Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia. Ann Hematol 95(4):657-9, 2016. e-Pub 2016. PMID: 26758271.
Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, Tang G, Reddy NM, Medeiros LJ, Lin P. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements Is associated with high P53 expression and a poor prognosis. Am J Surg Pathol 40(2):253-61, 2016. e-Pub 2016. PMID: 26448193.
Chen Z, Hu S. MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation. Blood 127(8):1072, 2016. e-Pub 2016. PMID: 27351033.
Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget 7(3):2401-16, 2016. e-Pub 2016. PMID: 26573234.
Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol 37(6):e150-2, 2015. e-Pub 2015. PMID: 26086872.
Wang W, Cortes JE, Lin P, Khoury JD, Ai D, Tang Z, Tang G, Jorgensen JL, Medeiros LJ, Hu S. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia 29(11):2263-6, 2015. e-Pub 2015. PMID: 25931274.
Liu W, Hu S, Konopleva M, Khoury JD, Kalhor N, Tang G, Bueso-Ramos CE, Jorgensen JL, Lin P, Medeiros LJ, Lu X. De novo MYC and BCL2 double-hit B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in pediatric and young adult patients associated with poor prognosis. Pediatr Hematol Oncol 32(8):535-47, 2015. e-Pub 2015. PMID: 26558423.
Liu H, Wang W, Tang G, Yin CC, Muzzafar T, Medeiros LJ, Hu S. Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking low-grade B-cell lymphoma. Histopathology 67(5):740-5, 2015. e-Pub 2015. PMID: 25809821.
Tang G, Fu B, Hu S, Lu X, Tang Z, Li S, Jabbar K, Khoury JD, Medeiros LJ, Wang SA. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol 90(10):882-7, 2015. e-Pub 2015. PMID: 26148174.
Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 126(14):1699-706, 2015. e-Pub 2015. PMID: 26243778.
Deng L, Song Y, Young KH, Hu S, Ding N, Song W, Li X, Shi Y, Huang H, Liu W, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L, Ying Z, Zhang C, Sun Y, Zhu J. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 6(28):25061-73, 2015. e-Pub 2015. PMID: 26314957.
Wang XJ, Medeiros LJ, Lin P, Yin CC, Hu S, Thompson MA, Li S. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol 39(9):1250-8, 2015. e-Pub 2015. PMID: 25828389.
Wang W, Xie W, Hu S. Cup-like blasts in B-lymphoblastic leukaemia. Br J Haematol 170(5):596, 2015. e-Pub 2015. PMID: 26132718.
Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: Clinicopathologic features of 11 cases. Am J Surg Pathol 39(8):1132-9, 2015. e-Pub 2015. PMID: 25828391.
Chen Z, Wang W, Rich A, Tang G, Hu S. Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases. Am J Hematol 90(8):E146-8, 2015. e-Pub 2015. PMID: 25960187.
Tang G, Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, DiNardo C, Medeiros LJ. Isolated del(5q) in patients following therapies for various malignancies may not all be clinically significant. Am J Clin Pathol 144(1):78-86, 2015. e-Pub 2015. PMID: 26071464.
Jaitly V, Wang W, Hu S. Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemia. Stem Cell Investig 2:13, 2015. e-Pub 2015. PMID: 27358881.
Li Y, Hu S, Zuo Z, Hong M, Lin P, Li S, Konoplev S, Wang Z, Khoury JD, Young KH, Medeiros LJ, Yin CC. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol 28(6):787-98, 2015. e-Pub 2015. PMID: 25743023.
Loghavi S, Alayed K, Aladily TN, Zuo Z, Ng SB, Tang G, Hu S, Yin CC, Miranda RN, Medeiros LJ, Khoury JD. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 8:65, 2015. e-Pub 2015. PMID: 26055271.
Wang XI, Yin CC, Qazilbash MH, Hu S, Lu G. Clinical significance of acquired cytogenetic clones in patients with treated follicular lymphoma. Clin Lymphoma Myeloma Leuk 15(5):262-9, 2015. e-Pub 2015. PMID: 25573378.
Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol 8:32, 2015. e-Pub 2015. PMID: 25888368.
Wang W, Hu S. Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32). Blood 125(18):2875, 2015. e-Pub 2015. PMID: 26120642.
Zuo Z, Maiti S, Hu S, Loghavi S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper LJ, Bueso-Ramos CE. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28(3):373-82, 2015. e-Pub 2015. PMID: 25216221.
Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, Goswami M, Yin CC, Lu G, Medeiros LJ, Tang G. Isolated +15 in bone marrow: disease-associated or a benign finding?. Leuk Res 39(1):72-6, 2015. e-Pub 2015. PMID: 25435027.
Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): A diagnostic challenge. Clin Lymphoma Myeloma Leuk 14(4):e115-8, 2014. e-Pub 2014. PMID: 24589157.
Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S, Patel A, Goswami M, Khoury JD, Garcia-Manero G, Medeiros LJ, Wang SA. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 89(8):813-8, 2014. e-Pub 2014. PMID: 24782398.
Tang G, Lu X, Wang SA, Roney EK, Zhang L, Hu S, Lu G, Medeiros LJ, Patel A. Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms. Int J Clin Exp Pathol 7(6):3196-201, 2014. e-Pub 2014. PMID: 25031740.
Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, Medeiros LJ, Lin P. Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge. Clin Lymphoma Myeloma Leuk 13(5):629-33, 2013. e-Pub 2013. PMID: 23800601.
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20):4021-31; quiz 4250, 2013. e-Pub 2013. PMID: 23449635.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715-24, 2013. e-Pub 2013. PMID: 23343832.
Manola A, Kourelis TV, Busman B, Hu S, Marks P, Thompson PD. Mastocytosis causing refractory hypotension after coronary angiography. Int J Cardiol 156(2):e43-4, 2012. e-Pub 2012. PMID: 21917341.
Bai B, Lu G, Hu S, Yin CC. t(1;3)(p36;p21) as the sole clonal abnormality in a case of refractory acute myeloid leukemia. N Am J Med Sci 5:235-238, 2012. e-Pub 2012.
Mei Y, Hahn AA, Hu S, Yang X. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J Biol Chem 286(41):35380-7, 2011. e-Pub 2011. PMID: 21849505.
Hu S, Mrak RE, Goldblatt PJ. Tripartite components of a hepatocellular carcinoma with distinct immunohistochemical and metastatic features. Conn Med 74(2):79-83, 2010. e-Pub 2010. PMID: 20218042.
Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133(3):415-26, 2008. e-Pub 2008. PMID: 18455983.
Hu S, Alcivar A, Qu L, Tang J, Yang X. cIAP2 inhibits antigen receptor signaling by targeting Bcl10 for degradation. Cell Cycle 5(13):1438-42, 2006. e-Pub 2006. PMID: 16775419.
Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, Tang J, Baens M, Ye H, Lee TH, Marynen P, Riley JL, Yang X. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 116(1):174-81, 2006. e-Pub 2006. PMID: 16395405.
Hu S, Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem 278(12):10055-60, 2003. e-Pub 2003. PMID: 12525502.
Alcivar A, Hu S, Tang J, Yang X. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene 22(2):291-7, 2003. e-Pub 2003. PMID: 12527898.
Hu S, Yang X. dFADD, a novel death domain-containing adapter protein for the Drosophila caspase DREDD. J Biol Chem 275(40):30761-4, 2000. e-Pub 2000. PMID: 10934188.
Hu S, Tamada K, Ni J, Vincenz C, Chen L. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics 62(1):103-7, 1999. e-Pub 1999. PMID: 10585776.
Guo RF, Ward PA, Hu S, McDuffie JE, Huber-Lang M, Shi MM. Molecular cloning and characterization of a novel human CC chemokine, SCYA26. Genomics 58(3):313-7, 1999. e-Pub 1999. PMID: 10373330.
Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM. Caspase-14 is a novel developmentally regulated protease. J Biol Chem 273(45):29648-53, 1998. e-Pub 1998. PMID: 9792675.
Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD95-induced apoptosis. J Biol Chem 272(28):17255-7, 1997. e-Pub 1997. PMID: 9211860.
Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem 272(15):9621-4, 1997. e-Pub 1997. PMID: 9092488.

Review Articles

Tang Z, Wang W, Toruner GA, Hu S, Fang H, Xu J, You MJ, Medeiros LJ, Khoury JD, Tang G. Optical genome mapping for detection of BCR::ABL1 - another tool in our toolbox. Genes (Basel) 15(11):1383, 2024. e-Pub 2024. PMID: 39596583.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th Edition of The World Health Organization Classification of Haematolymphoid Tumors: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36(7):1703-1719, 2022. e-Pub 2022. PMID: 35732831.
El Hussein S, Medeiros LJ, Hu S, Lin P, Wang W. The many faces of plasma cell neoplasms: morphological and immunophenotypical variants of the great imitator. Pathology 54(1):32-42, 2022. e-Pub 2022. PMID: 34887091.
Zhou T, Medeiros LJ, Hu S. Chronic myeloid leukemia: Beyond BCR-ABL1. Curr Hematol Malig Rep 13(6):435-445, 2018. e-Pub 2018. PMID: 30370478.
Gong Z, Wang W, Hu S. Cytogenetic alterations in CML: not all created equal. Oncotarget 9(15):11885-11886, 2018. e-Pub 2018. PMID: 29552278.
Gong Z, Hu S. Recent advances in diagnosis and management of chronic neutrophilic leukemia. Chin J Practical Internal Med 38(2):123-126, 2018. e-Pub 2018.
Hu S, Young KH, Konoplev SN, Medeiros LJ. Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol 43(11):1789-98, 2012. e-Pub 2012. PMID: 22959759.
Park SM, Hu S, Lee TH, Yang X. Ubiquitination mediated by inhibitor of apoptosis proteins. Methods Enzymol 446:225-35, 2008. e-Pub 2008. PMID: 18603125.

Abstracts

Wei Q, Jen WY, Hu S, Wang SA, Toruner GA, Xu J, Li S, Loghavi S, Ok CY, Leventaki V, Medeiros LJ, Tang G. Genetic heterogeneity and diagnostic challenges of MECOM-rearranged myeloid neoplasms: insights from optical genome mapping. Lab Invest, 2026.
Wei Q, Jen WY, Wang SA, Hu S, Xu J, Li S, Loghavi S, Ok CY, Leventaki V, Medeiros LJ, Tang G. Characterization of classic and variant MECOM rearrangements in a cohort of 312 patients. Lab Invest, 2026.
Zhang Z, Medeiros LJ, Tang G, Hu S. Clinicopathologic and genetic distinctions of dual BCL2/BCL6-rearranged follicular lymphoma compared to other cytogenetic subgroups. Lab Invest, 2026.
Wong J, Zou Y, Zhou Q, Tang G, Wang W, Chang H, Medeiros LJ, Hu S. AML-defining genetic abnormalities represent high-risk factors in blastic transformation of CML. Lab Invest, 2026.
Al-Rusan O, Wang W, Wang SA, Jorgensen J, Tang G, Medeiros LJ, Hu S. Significance of low-level lymphoblasts in acute myeloid leukemia. Lab Invest, 2026.
Toruner GA, Tang G, Loghavi S, Agarwal NK, Kanagal-Shamanna K, Hu S, Jelloul F, Routbort MJ, Yin CC, Sarami I, Garces S, Iorguluescu B, Wei Q, Quesada A, Medeiros LJ, Patel KP. Comparative analysis of targeted RNA-Seq and optical genome mapping for detecting clinically significant gene rearrangements. Cancer Genet, 2025. e-Pub 2025.
Wei Q, Xu J, Hu S, Toruner G, Loghavi S, Li S, Wang W, Medeiros LJ, Guilin Tang G. KMT2A PTD Is associated with aberrant CD25 and CD123 expression, FLT3 and DNMT3A mutations, and therapeutic resistance in myeloid neoplasms. Lab Invest 105(3):Supplement, 103546, 2025. e-Pub 2025.
Loghavi S, Routbort M, Daver N, DiNardo C, Short NJ, Wang SA, Wang W, Amin H, Leventaki V, Jorgensen J, Xu J, Ok CY, Quesada AE, Schlette E, Bueso-Ramos CE, Fang H, Hu S, Li S, Lin P, Garces SA, Tapan KM, Issa G, Yilmaz M, Hammond D, Montalban-Bravo G, Jabbour EJ, Kantarjian HM, Ravandi-Kashani F, Medeiros LJ, Patel KP. FLT3 internal tandem duplication detection using ultrasensitive error-corrected NGS improves identification of measurable residual acute myeloid leukemia. Lab Invest 105(3):Supplement, 103487, 2025. e-Pub 2025.
Wei Q, Hu S, Xu J, Loghavi S, Toruner GA, Li S, Medeiros LJ, Tang G. Chromoanagenesis: A common mechanism that leads to highly complex karyotypes, clonal heterogeneity and treatment refractoriness in myelodysplastic syndromes. Lab Invest 105(3):Supplement, 103548, 2025. e-Pub 2025.
Wang WJ, Tang G, Lin P, Wang W, Medeiros LJ, Hu S. Mixed-phenotype acute leukemia with TP53 mutation: a study of 28 patients. Lab Invest 105(3):Supplement, 103543, 2025. e-Pub 2025.
Wang WJ, Hu S, Xu J, Quesada AE, Loghavi S, Li S, Medeiros LJ, Tang G. The value of optical genome mapping in diagnostically challenging cases of low-grade B-cell lymphoma. Lab Invest 105(3):Supplement, 103544, 2025. e-Pub 2025.
Shen Q, Liu M, Tang G, Wang W, Zhang Z, Medeiros LJ, Hu S. Unusual indolent CM: stable non-responders after 10 years of TKI therapy. Lab Invest 105(3):Supplement, 103525, 2025. e-Pub 2025.
Wei Q, Hu S, Loghavi S, Toruner GA, Xu J, Li S, Medeiros LJ, Tang G. Utility of optical genome mapping in myelodysplastic syndrome: pros and limitations. Lab Invest 105(3):Supplement, 103547, 2025. e-Pub 2025.
Xie W, Hu S, Wisznieska J, Traer E, Dunlap J, Wang E, Zhang L, Hu Z. Secondary acquisition of the Philadelphia chromosome during myeloid neoplasm therapy reveals two distinct pathways with unique clinical implication. Lab Invest 105(3):Supplement, 103553, 2025. e-Pub 2025.
Hu Z, Shi A, Liu JM, Liu J, Ha X, Wang W, Hu S, Shuai W, Wang SA, You MJ, Sun X, Hansel DE, Chen L, Hirsch-Ginsberg C. Artificial intelligence-assisted image analysis of peripheral blood smears to aid in the diagnosis and monitoring of acute promyelocytic leukemia. Lab Invest 105(3):Supplement, 103468, 2025. e-Pub 2025.
Quesada AE, Zou Y, Bueso-Ramos CE, Hu S, Toruner GA, Jelloul FZ, Patel KP, Medeiros LJ, Tang G. Myeloid neoplasms with MYC amplification are associated with TET2 and TP53 mutations, chromoanagenesis, treatment refractoriness and poor outcomes. J Mol Diagn 26(11):S45 (Abstract H044), 2024. e-Pub 2024.
Toruner GA, Hu S, Tang Z, Loghavi S, Kanagal-Shamanna R, Ok CY, Medeiros LJ, Tang G. Clinical utility of optical genome mapping as an additional test to standard cytogenetic workup in hematological malignancies. J Mol Diagn 26(11):S38 (Abstract H023), 2024. e-Pub 2024.
Loghavi S, Wang SA, Jen WY, Wang W, Fang H, Li S, Garces S, Quesada A, Xu J, Ok CY, Hu S, Jorgensen JL, Tang G, Nasnas C, Karrar O, Issa G, Daver N, DiNardo CD, Kadia TM, Kantarjian HM, Medeiros LJ, Ravandi F, Short NJ. Myeloid progenitor cells with preleukemic immunophenotypes are commonly seen in myelodysplasia-related and NPM1-mutated acute myeloid leukemia (AML) and should not be interpreted as measurable residual disease (MRD). Blood 144(Supplement 1):4336, 2024. e-Pub 2024.
Lai X, Hu CY, Tang G, Wang W, Patel KP, You MJ, Medeiros LJ, Hu S. Mutational profile of B-lymphoblastic leukemia with BCR::ABL1. Lab Invest 104(Suppl):S1438, 2024. e-Pub 2024.
Wei Q, Toruner GA, Hu S, Loghavi S, Li S, Xu J, Kanagal-Shamanna R, Medeiros LJ, Tang G. Comprehensive cytogenomic profile of adult Ph-negative B-lymphoblastic leukemia by optical genome mapping and standard cytogenetic testing. Lab Invest 104(Suppl):S1500, 2024. e-Pub 2024.
Toruner GA, Tang Z, Hu S, Loghavi S, Kanagal-Shamanna R, Medeiros LJ, Tang G. Clinical utility of optical genome mapping as an additional test to standard cytogenetic workup in hematological malignancies. Genet Med Open 2(Suppl 1):101489 (P583), 2024. e-Pub 2024.
Hu S, Lai X, Hu CY, Wang W, Loghavi S, Medeiros LJ, Tang G. Genetic profile of mixed-phenotype acute leukemia with BCR::ABL1/ mixed-phenotype blast phase of chronic myeloid leukemia. Lab Invest 104(Suppl):S1415, 2024. e-Pub 2024.
Hu AY, Zhang L, Gao J, Wu X, Shao L, Zheng G, Quesada A, Wang E, Cui W, Xu X, Zhou Y, Lu X, Song J, Wang X, Tang G, Patel KP, Medeiros LJ, Hu S. Is idic(X)(q13) a myelodysplasia-defining genetic alteration in MDS and AML?. Lab Invest 104(Suppl):S1414-1415, 2024. e-Pub 2024.
Parisi X, Wang W, Liu W, Loghavi S, Hu S, Jelloul FZ, Medeiros LJ, Fang H. Reactive intra-sinusoidal immunoblastic proliferations in lymph nodes: A diagnostic pitfall for diffuse large B-cell lymphoma. Lab Invest 104(Suppl):S1462-1463, 2024. e-Pub 2024.
E S, Vega F, Khanlari M, Fang H, Xu J, Li S, Hu S, Wang SA, Lj M, Wang W. BCL11B helps to define T-lineage in cases of lymphoma/leukemia with a mixed or ambiguous phenotype. Lab Invest 104(Suppl):S1400-1401, 2024. e-Pub 2024.
E S, Yin CC, Hu S, Wei Q, Medeiros LJ, Wang W. Immunophenotypic and molecular landscapes of four types of acute leukemia derived from very early progenitors. Lab Invest 104(Suppl):S1399-1400, 2024. e-Pub 2024.
Gong Z, Qiu L, DiGiuseppe JA, Xue M, Soma L, Wang W, Zhou Y, Shen Q, Zhu M, Naik A, Chen W, Wang WJ, Wang SA, Medeiros LJ, Jabbour E, Kantarjian HM, Cortes JE, Radich J, Khoury JD, Hochhaus A, Apperley JF, Chen S, Naresh KN, Hu S. Does detection of <20% lymphoblasts in patients with CML herald imminent blast crisis? A study from BCR::ABL1 Pathology Group. Blood 142(Suppl 1):6364, 2023. e-Pub 2023.
Quesada AE, Toruner AG, Tang Z, Hu S, Xu J, Li S, Ravandi-Kashani F, Kantarjian H, You MJ, Medeiros LJ, Tang G. Optical genomic mapping provides unique findings in various types of myeloid neoplasms. Blood 142(Suppl 1):4303, 2023. e-Pub 2023.
Wei Q, Tang G, Toruner GA, Tang Z, Loghavi S, Hu S, Medeiros LJ. Chromoanagenesis: a common mechanism that leads to highly complex karyotype and extensive clonal heterogeneity in hematological malignancies. J Mol Diagn 25(11):S37, 2023. e-Pub 2023.
Tang Z, Tang G, Toruner GA, Hu S, Yang S, Khoury JD, Medeiros LJ. Diagnostic challenges of 3q26.2 aberrations/MECOM rearrangement: an extended study from a single institute. J Mol Diagn 25(6):S17, 2023. e-Pub 2023.
Nirmalanantham P, Hu S, Li S, Xu J, Tang G, Lin P. Deletion of CDKN2C is associated with deletion of RB, gains or amplification of CKS1B. Lab Invest 103(Suppl):S1213, 2023. e-Pub 2023.
Liu M, Wang X, E S, Tang G, Wang W, Jelloul FZ, Lin P, Medeiros LJ, Hu S. Myeloid neoplasms with t(2;3)(p21~23;3q26.2): a report of 21 cases. Lab Invest 103(Suppl):S1184, 2023. e-Pub 2023.
Nahmod KA, Tang Z, Lin P, Toruner GA, Li S, Xu J, Hu S, Medeiros LJ, Tang G. Cytogenetic clonal evolution in plasma cell neoplasms. Lab Invest 103(Suppl):S1209, 2023. e-Pub 2023.
Rivera D, E S, Cui W, Zhang Q, Dewar R, Wang H, Hu Z, Wang W, Medeiros LJ, Hu S. Smoldering phase of CML without leukocytosis and thrombocytosis at initial presentation: a multi-institutional study of 31 cases. Lab Invest 103(Suppl):S1226, 2023. e-Pub 2023.
Fang H, Beird HC, Wang SA, Ibrahim A, Tang Z, You MJ, Futreal A, Hu S, Yin CC, Thakral B, Medeiros LJ, Wang W. Characterization of a novel type of mature CD4-positive T-cell leukemia that primarily involved peripheral blood and bone marrow. Lab Invest 103(Suppl):S1131, 2023. e-Pub 2023.
E S, Liu M, Fang H, Wang W, Tang G, Medeiros LJ, Hu S. Immunophenotypic landscape and prognosis of patients with blast phase of chronic myeloid leukemia in the last decade: a study of 236 cases. Lab Invest 103(Suppl):S1126-1127, 2023. e-Pub 2023.
Nahmod KA, Wang SA, Li S, Tang Z, Aakash F, Xu J, Hu S, Medeiros LJ, Tang G. Immunophenotype and cytogenetic abnormalities in plasma cells of lymphoplasmacytic lymphoma and their roles in differential diagnosis. Lab Invest 103(Suppl):S1209-1210, 2023. e-Pub 2023.
Fang H, Wang SA, El Hussein S, Konoplev SN, Mo H, Liu W, Zuo Z, Hu S, Jelloul F, Tang Z, Medeiros LJ, Wang W. Acute promyelocytic leukemia: its immunophenotype and differential diagnosis. Lab Invest 102(Suppl 1):879, 2022. e-Pub 2022.
Nwogbo OV, Hu S, Hao S, Li S, Xu J, Yin C, Bueso-Ramos C, Tang G, Medeiros LJ, Lin P. Prognostic impact of 8q24/MYC gene rearrangement in myeloma in the era of novel therapy. Lab Invest 102(Suppl 1):997, 2022. e-Pub 2022.
Wang X, Hu S, Medeiros LJ. Clinical and pathological characteristics of leukemic phase of double-/triple-hit lymphoma. Lab Invest 102(Suppl 1):1034-1035, 2022. e-Pub 2022.
Xie W, Hoyos CM, Li H, Li P, Olson SB, Press R, Yang F, Anekpuritanang, Hu S, Wiszniewska J, Dunlap J, Raess PW, Fan G, Moore SR. Clinicopathologic features of acute myeloid leukemia with NUP98 rearrangement. J Mol Diagn 23(11):1583 (Abstract H22), 2021. e-Pub 2021.
Hu Z, Xu ML, Yuan J, Peker D, Shao L, Rios A, Medeiros LJ, Hu S. T-cell prolymphocytic leukemia with t(X;14)(q28;q11.2): a report of 17 cases. Lab Invest 101(Suppl 1):844, 2021. e-Pub 2021.
Fang H, Khoury JD, Torres-Cabala CA, Ng S, El Hussein S, Hu S, Medeiros LJ, Wang W. Expression pattern and diagnostic utility of BCL11B in T and NK-cell neoplasms. Lab Invest 101(Suppl 1):823-824, 2021. e-Pub 2021.
Wang X, Tang G, Hu Z, Wang W, Toruner, GA, Tang Z, Bueso-Ramos CE, Medeiros LJ, Hu S. Acute myeloid leukemia and myelodysplastic syndrome with MYC rearrangement. Lab Invest 101(Suppl 1):903-904, 2021. e-Pub 2021.
Mai B, Wang WJ, Shuai W, Wang XI, Chen L, Ma HY, Wahed A, Hu S, Nguyen N, Hu Z. The diagnostic and prognostic roles of EBER for patients with HIV-associated aggressive non-Hodgkin lymphomas in the era of HAART. Lab Invest 101(Suppl 1):926-927, 2021. e-Pub 2021.
Yang R, Tang Z, Tang G, Toruner G, Yin CC, Wang W, Hu S, Zuo Z, Patel K, Khoury J, Medeiros LJ. Atypical CBFB FISH signal patterns warrant further investigation for a true CBFB rearrangement: an analysis of 2,425 CBFB FISH tests. J Mol Diagn 22(11):S22-23, 2020. e-Pub 2020.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Exploring the molecular grey zone of myeloid neoplasms: concurrent SRSF2 and classic MPN drive mutations. Clin Lymphoma Myeloma Leuk 20(Suppl 1):S340, 2020. e-Pub 2020.
Fang H, Yabe M, Zhang X, Kim Y, Shen Y, Shao L, Ji Y, Wu X, Zheng G, Shen Q, Yuan Y, He R, Chen D, Medeiros LJ, Hu S. Myelodysplastic syndrome with t(6;9)(p22;q34.1) categorized as acute myeloid leukemia: a large multicenter study of 105 cases. Lab Invest 100(Suppl 1):1281, 2020. e-Pub 2020.
Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen S, Zhou Y, Loghavi S, Wang SA, Bueso-Ramos C, Medeiros LJ, Hu S. t(11;16)(q23;p13) and t(2;11)(p21;q23) in hematologic neoplasms: presumptive evidence of myelodysplasia revisited. Lab Invest 100(Suppl 1):1410, 2020. e-Pub 2020.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, Kanagal-Shamanna R, Luthra R, Hu S, Khanlari M, El Hussein S, Lin P, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Exploring the molecular grey zone of myeloid neoplasms: concurrent SRSF2 and classic MPN drive mutations. Lab Invest 100(Suppl 1):1395-1396, 2020. e-Pub 2020.
Fang H, Beird HC, Hu S, Bueso-Ramos C, Tang G, Tang Z, You MJ, Khoury JD, Medeiros LJ, Wang W. t(6;14)(q25;q32) involves BCL11B and is highly associated with mixed phenotype acute leukemia, T/myeloid. Lab Invest 100(Suppl 1):1280-1281, 2020. e-Pub 2020.
Hu Z, Chen W, Wang W, Mai B, Nguyen N, Medeiros LJ, Hu S. Primary effusion lymphoma: a clinicopathological study of 29 cases. Lab Invest 100(Suppl 1):1308, 2020. e-Pub 2020.
Toruner G, Tang Z, Tang G, Medeiros LJ, Hu S. Clonal size of ALK rearrangements detected by FISH is associated with the duration of progression free survival in metastatic lung cancer treated with ALK inhibitor. Cancer Genet 233(Suppl):S20, 2019. e-Pub 2019.
Xie W, Tang G, Zhou T, Xu J, Medeiros LJ, Hu S. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adult patients. Lab Invest 99(Suppl 1):160, 2019. e-Pub 2019.
Shuai W, Lin P, Routbort MJ, Patel KP, Hu S, Thakral B, Zhong B, Medeiros LJ, Wang W. Distinct clinicopathologic features of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) based on MYD88 mutations at hotspot versus non-hotspot codons. Lab Invest 99(Suppl 1):139-141, 2019. e-Pub 2019.
Lin M, Wang W, Aakash N, Hu S, Brown RE, Wang XI, Chen L, Wahed A, Nguyen N, Medeiros LJ, Hu Z. HIV-associated plasmablastic lymphoma: ten-year experience in the era of highly active antiretroviral therapy. Lab Invest 99(Suppl 1):89-90, 2019. e-Pub 2019.
Chen Z, Wang SA, Hu S, Li S, Tang Z, Toruner G, Medeiros LJ, Tang G. Is hyperdiploidy favorable in adult B-lymphoblastic leukemia?. Lab Invest 99(Suppl 1):23-24, 2019. e-Pub 2019.
Zhou T, Gong Y, Gong Z, Hu AY, Wang W, Medeiros LJ, Hu S. Body fluid blast phase of chronic myeloid leukemia. Lab Invest 99(Suppl 1):175, 2019. e-Pub 2019.
Hao S, Konoplev S, Lu X, Li S, Hu S, Xu J, Tang G, Medeiros LJ, Lin P. The survival impact of 1q+/CKS1B depends on background karyotype and del(17)/TP53 allelic burden. Lab Invest 99(Suppl 1):62, 2019. e-Pub 2019.
Gong Z, Chen M, Xu ML, Cui W, Zhou T, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative “blast phase” of chronic myeloid leukemia. Lab Invest 99(Suppl 1):Suppl 1, 2019. e-Pub 2019.
Xie W, Ruiz-Cordero R, Hu S, Medeiros LJ, Fountain E, Manasanch E, Lin P. Nanostring platform using formalin-fixed praraffin-embedded for risk prediction in multiple myeloma. Lab Invest 99(Suppl 1):166, 2019. e-Pub 2019.
Shen J, Li S, Yin CC, Wang SA, Lin P, Jorgensen J, Tang G, Hu S, Medeiros LJ, Xu J. CD8 expression in anaplastic large cell lymphoma identifies a subgroup with advanced stage, non-common morphology, unique phenotype, and poorer outcome. Lab Invest 99(Suppl 1):138-139, 2019. e-Pub 2019.
Xie W, Wang SA, Chen Z, Li S, Miranda RN, Hu S, Medeiros LJ, Tang G. Myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms followed by acute lymphoblastic leukemia. Lab Invest 99(Suppl 1):167, 2019. e-Pub 2019.
Luedke C, Hu S, Zhao Y, Pan Z, Song J, Bueso-Ramos C, Medeiros LJ, Wang E. Two distinct pathways for the development of plasmablastic lymphoma in the setting of chronic lymphocytic leukemia: Richter transformation-like clonal evolution and Epstein-Barr virus associated de novo B-cell neoplasm. Lab Invest 99(Suppl 1):90, 2019. e-Pub 2019.
Zhou T, Tang G, Loghavi S, Kurt H, Medeiros LJ, Hu S. Significance of idic(X)(q13) in myeloid neoplasms. Poster presentation. Lab Invest 99(Suppl 1):175-176, 2019. e-Pub 2019.
Tang Z, Wang W, Tang G, Pemmaraju N, Hu S, Yin CC, Konopleva M, Toruner G, Medeiros LJ, Khoury JD. ETV6 deletion as a potential biomarker for BPDCN. Am J Hum Genet, 2018. e-Pub 2018.
Aboudalle I, Khan M, Feng L, Thomas SK, Manasanch EE, Patel KK, Medeiros LJ, Mehta R, Bashir Q, Qazilbash MH, Orlowski RZ, Weber DM, Hu S, Lee HC. Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: single center experience. J Clin Oncol 36(15_suppl):8054, 2018. e-Pub 2018.
Doty M, Chu C, Zhao M, Gu J, Hu P, Hu S. Myc rearrangement involved in myeloid neoplasms associated with the t(3;8)(q26.2;q24). Ann Clin Lab Sci 48(3), 2018. e-Pub 2018.
Ronaghy A, Lin P, Wang W, Hu Z, Medeiros LJ, Hu S. Myeloid neoplasm with t(3;12)(q26.2;p13)/ETV6-EVI1 rearrangement: a study of 12 cases. Lab Invest 98(Supp 1):548, 2018. e-Pub 2018.
Hidalgo-Lopez J, Quesada A, Gong Z, Wang W, Kanagal-Shamanna R, Hu S, Yin CC, Cortes JE, Bassett Jr R, Medeiros LJ, Kantarjian KP, Bueso-Ramos CE. Indications for bone marrow biopsy at time of first assessment in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Lab Invest 98(Supp 1):521, 2018. e-Pub 2018.
Rahman H, Khoury JD, Bueso-Ramos CE, McDonnell T, Salem A, Wang SA, Muzzafar T, Tetzlaff M, Bell D, Khogeer H, Angelova E, Tang G, Hu S, Patel KP, Routbort M, Luthra R, Lin P, Medeiros LJ, Loghavi S. Aberrant cytokeratin expression in acute myeloid leukemia is associated with complex karyotype and TP53 alteration. Lab Invest 98(Suppl 1):546, 2018. e-Pub 2018.
Xie W, Wang J, Chen Z, Tang G, Wang S, Loghavi S, Medeiros LJ, Hu S. Myeloid neoplasm with t(11;16)(q23;p13): a study of 11 cases. Lab Invest 98(Supp 1):565, 2018. e-Pub 2018.
Sakhdari A, Patel KP, Ok CY, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort M, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Lab Invest 98(Supp 1):549, 2018. e-Pub 2018.
Garces S, Huang W, Li S, Hu S, Wang W, Yin CC, Xu J, Medeiros LJ, Lin P. Clinicopathologic and immunophenotypic features of MYD88 L265P-positive lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia (LPL/WM): a study of 30 cases. Lab Invest 98(Supp 1):517, 2018. e-Pub 2018.
He J, Lu X, Li S, Hu S, Wang W, Yin CC, Medeiros LJ, Lin P. t(14;16)/IGH-MAF in multiple myeloma is associated with other high-risk genetic features. Lab Invest 98(Supp 1):521, 2018. e-Pub 2018.
Hu Z, Hu S, Wang XI, Medeiros LJ, Wang W. Characterization of 3q26.2/EVI1 rearrangements in myelodysplastic/myeloproliferative neoplasms. Lab Invest 98(Supp 1):522, 2018. e-Pub 2018.
Tang G, Hu S, Tang Z, Toruner G, Medeiros LJ, Xie W. t(3;8)(q26.2;q24) is commonly associated with therapy-related myeloid neoplasms and involves MECOM/MYC rearrangement. Am J Hum Genet, 2018. e-Pub 2018.
Jain P, Kanagal-Shamanna R, Ghorab A, Nastoupil L, Fayad LE, Medeiros J, Hu S, Neelapu SS, Westin JR, Oki Y, Wang M, Fowler NH. Characteristics, treatments, and outcomes of patients with lymphomatoid granulomatosis—MD Anderson Cancer Center experience. Blood 130(Suppl 1):2852, 2017. e-Pub 2017.
Gong Z, Chen Z, Verstovsek, Cortes JE, Ronaghy A, Wang W, Bueso-Ramos C, Medeiros LJ, Hu S. Impact of i(17q) in myeloproliferative neoplasms. Blood 130(Suppl 1):2911, 2017. e-Pub 2017.
Gong Z, Medeiros LJ, Cortes JE, Wang W, Kantarjian HM, Hu S. Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors. Blood 130(Supp 1):247, 2017. e-Pub 2017.
Fang L, Lu X, Hu S, Tang Z, Luthra R, Routbort MJ, Patel KP, Broaddus R, Chen H. MET amplification predicts primary resistance to EGFR-TKIs in advanced non-small cell lung cancer patients with sensitive EGFR mutation. J Mol Diagn 19(6):1032, 2017. e-Pub 2017.
Hidalgo-Lopez J, Quesada A, Gong Z, Wang W, Kanagal-Shamanna R, Hu S, Yin CC, Cortes JE, Bassett Jr R, Medeiros LJ, Kantarjian KP, Bueso-Ramos CE. Diagnostic utility of bone marrow biopsy in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 17(Suppl 1):S306-S307, 2017. e-Pub 2017.
Gong Z, Bai S, Chen Z, Wang W, Miranda RN, Medeiros LJ, Hu S. Differential impact of TKI therapy on the natural course of CML determines risk stratification of additional cytogenetic abnormalities. Lab Invest 97(Suppl 1):351A, 2017. e-Pub 2017.
Fang L, Chen H, Medeiros LJ, Hu S, Lin P, Luthra R, Singh RR, Routbort MJ, Hong D, Meric-Bernstam F, Lu X. Optimization of MET FISH reporting criteria in non-small cell lung cancer: MD Anderson experience. Lab Invest 97:507A, 2017. e-Pub 2017.
Zheng L, Han X, Gong Z, Medeiros LJ, Hu S. Secondary t(9;22)(q34;q11.2)/BCR-ABL1 rearrangement is a fatal event in myeloid/lymphoid neoplasm. Lab Invest 97(Suppl 1):388A, 2017. e-Pub 2017.
Gong Z, Tang Z, Chen Z, Wang W, Bai S, Tang G, Medeiros LJ, Hu S. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia. Lab Invest 97(Suppl 1):350A-351A, 2017. e-Pub 2017.
Hu Z, Wang W, Chen Z, Gong Z, Hodjat P, Bai S, Tang G, Medeiros LJ, Hu S. 3q26.2 rearrangements are associated with a poor prognosis in Ph-negative myeloproliferative neoplasms. Lab Invest 97(Suppl 1):355A, 2017. e-Pub 2017.
Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu ML. Tissue based chimerism analysis enhances detection of donor derived neoplasm in allogeneic stem cell transplant patients. Lab Invest 97(Suppl 1):338A-339A, 2017. e-Pub 2017.
Chen Z, Wang W, Medeiros LJ, Hu S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Lab Invest 97(Suppl 1):342A, 2017. e-Pub 2017.
Fang L, Chen H, Medeiros LJ, Hu S, Lin P, Luthra R, Singh RR, Routbort MJ, Hong D, Meric-Bernstam F, Lu X. Correlation between MET gene copy number and molecular profiling in non-small cell lung cancer. Lab Invest 97(Suppl 1):478A, 2017. e-Pub 2017.
Chen Z, Medeiros LJ, Gong Z, Zheng L, Patel KP, Wang W, Hu S. Requirement of depth of treatment response for optimal outcome in patients with blast phase of chronic myeloid leukemia. Lab Invest 97(Suppl 1):342A, 2017. e-Pub 2017.
Salem A, Tang G, Loghavi S, Hu S, Medeiros LJ, Khoury JD. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB-MYH11 rearrangements: clinicopathologic features and treatment implications. Lab Invest 97(Suppl 1):374A-375A, 2017. e-Pub 2017.
Bai S, Chen Z, Wang W, Hu Z, Medeiros LJ, Hu S. inv(3)/t(3;3)(q21;q26) in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Lab Invest 97(Suppl 1):338A, 2017. e-Pub 2017.
Gong Z, Bai S, Chen Z, Wang W, Medeiros LJ, Hu S. Mixed-phenotype blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Blood 128(22):5438, 2016. e-Pub 2016.
Jain P, Kantarjian HM, Jabbour EJ, Gonzalez GN, Garcia-Manero G, Kanagal-Shamanna R, Patel KP, Hu S, DellaSala SM, Pierce S, Sasaki K, Konopleva M, Wierda WG, Daver N, Kadia TM, Borthakur G, Estrov Z, Ravandi F, O’Brien SM, Cortes JE. Factors affecting survival outcomes in patients with blast phase CML (CML-BP) in the tyrosine kinase inhibitor (TKI) era: a cohort study of 498 patients. Blood 128(22):1220, 2016. e-Pub 2016.
Regmi K, Hu PC, Gu J, Gu J, Zhao M, Tang Z, Hu S. Prognostic impact of MYC rearrangement in plasma cell myeloma. J Assoc Genet Technol 42(3):141, 2016. e-Pub 2016.
Chen Z, Wang W, Medeiros LJ, Hu S. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Lab Invest 96(Suppl 1):339A, 2016. e-Pub 2016.
Costinean S, Zheng M, Huang X, Meng B, Smith LM, Appiah AK, Hu S, Zhou Y, Pan Z, Greiner TC, Qureishi HN, Amador C, Fu K, Yuan J. Activation of JAK3/STAT3 pathway is associated with inferior outcome in diffuse large B-cell lymphoma and ALK-positive large B-cell lymphoma. Lab Invest 96(Suppl 1):340A-341A, 2016. e-Pub 2016.
Hu Z, Medeiros LJ, Tang G, Tang Z, Hu S, Lin P, Lu X. Complex karyotypes predict a poorer prognosis in T-cell prolymphocytic leukemia. Lab Invest 96(Suppl 1):353A, 2016. e-Pub 2016.
Pan Z, Hu S, Li M, Zhou Y, Kim YS, Reddy V, Gao Z, Wang H, Yuan J. ALK-positive diffuse large B-cell lymphoma: a clinicopathologic study of 25 cases with review of additional 108 cases in the literature. Lab Invest 96(Suppl 1):367A, 2016. e-Pub 2016.
Liu W, Li S, Lu G, Chen Z, Lu X, Yuan J, Medeiros LJ, Hu S. Prognostic importance of MYC deletion detected by fluorescence in situ hybridization in paraffin sections in diffuse large B-cell lymphoma. Lab Invest 96(Suppl 1):359A, 2016. e-Pub 2016.
Wang W, Cortes J, Tang G, Khoury JD, Wang S, Bueso-Ramos C, DiGiuseppe JA, Chen Z, Kantarjian H, Medeiros LJ, Hu S. Risk stratification of additional chromosomal changes in chronic myelogenous leukemia in era of tyrosine kinase inhibitor therapy. Lab Invest 96(Suppl 1):382A-383A, 2016. e-Pub 2016.
Xie W, Wang W, Yuan J, Zhou Y, Medeiros LJ, Hu S. T-lymphoblastic blast crisis of chronic myelogenous leukemia, a study of 14 cases. Poster presentation. Lab Invest 96(Suppl 1):385A, 2016. e-Pub 2016.
Thakral B, Desai P, Lin P, Yin CC, Tang G, Hu S, Khoury JD, Medeiros LJ, Li S. Prognostic significance of CD5 expression in diffuse large B-cell lymphoma in patients treated with Rituximab-EPOCH. Lab Invest 96(Suppl 1):378A, 2016. e-Pub 2016.
Goswami R, Wang SA, Li Y, Hu S, Medeiros LJ, Tang G. Newly emerged isolated del(7q) may not always be associated with therapy-related myeloid neoplasms in patients with prior cytotoxic therapies. Lab Invest 96(Suppl 1):347A-348A, 2016. e-Pub 2016.
Li Y, Hu S, Wang SA, Huh YO, Li S, Medeiros LJ, Tang G. MYC rearrangement in chronic lymphocytic leukemia is not often associated with poor prognosis. Lab Invest 96(Suppl 1):358A, 2016. e-Pub 2016.
Hu Z, Wang W, Chen Z, Tang G, Lu X, Li S, Medeiros LJ, Hu S. Mantle cell lymphoma with MYC rearrangement: best considered as a form of double-hit lymphoma?. Lab Invest 96(Suppl 1):353A, 2016. e-Pub 2016.
Hao S, Konoplev S, Orlowski R, Medeiros LJ, Hu S, Lin P, Lu X. Cytogenetic subgroups and their clinical implications in multiple myeloma patients with TP53 deletion. Lab Invest 96(Suppl 1):350A, 2016. e-Pub 2016.
Jain P, Patel KP, Futreal A, Gumbs C, Hu S, Bueso Ramos C, Wang M, Romaguera J, Fayad LE, Orlowski RZ, Medeiros LJ, Fowler N. Clinico-pathologic characteristics, treatments and outcomes of patients with dendritic cell sarcoma. Poster presentation. Blood 126(23):2700, 2015. e-Pub 2015.
Liu W, Tamayo A, Chen J, Hu S, Ford RJ, Pham L. Preclinical evaluation of the oral proteasome inhibitor Ixazomib in diffuse large B-cell lymphoma. Blood 126(23):4003, 2015. e-Pub 2015.
Wang W, Cortes J, Lin P, Khoury JD, Ai D, Tang Z, Tang G, Jorgensen J, Medeiros LJ, Hu S. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 15(Suppl 1):S31-32, 2015. e-Pub 2015.
Ye Q, Xu-Monette ZY, Hu S, Tzankov A, Gisin N, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards K, His ED, Choi WWL, van Kireken H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Go RS, Winter JN, Piris MA, Medeiros LJ, Young KH. Clinical and biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Clin Lymphoma Myeloma Leuk 15(Suppl 1):S228, 2015. e-Pub 2015.
Hong S, Zhao M, Gu J, Hopwood VL, Lu G, Hu S. PAX5 rearrangement in plasma cell myeloma. J Assoc Genet Technol 41(3), 2015. e-Pub 2015.
Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HA, McDonnell TJ, Kantarjian H, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 15(Suppl 1):S32-33, 2015. e-Pub 2015.
Shen Q, Li S, Chen M, Song JY, Lu G, Tang G, Hu S, Wang XI, Lin P, Medeiros LJ, Yin CC. Acute myeloid leukemia/myelodysplastic syndrome with t(3;5): clinicopathologic, immunophenotypic, and molecular genetic features of 16 cases. Lab Invest 95(Suppl 1):377A, 2015. e-Pub 2015.
Liu H, Liu W, Lin P, Jorgensen JL, Medeiros LJ, Hu S. Lymphomatous presentation of hairy cell leukemia, a diagnostic challenge and a prognostic factor. Lab Invest 95(Suppl 1):360A, 2015. e-Pub 2015.
Goswami RS, Liang CS, Hu S, Medeiros LJ, Tang G. Isolated del(5q) in patients following cytotoxic therapy- are all associated with therapy-related myeloid neoplasms. Lab Invest 95(Suppl 1):347A, 2015. e-Pub 2015.
Wang W, Hu S, Lu X, Young KH, Medeiros, LJ. Triple-hit B-cell lymphomas with MYC, BCL2 and BCL6 translocations: morphological, immunophenotypic and clinical features. Lab Invest 95(Suppl 1):384A, 2015. e-Pub 2015.
Wang W, Ai A, Liu H, Bueso-Ramos CE, Medeiros LJ, Hu S. Balanced 11q23/MLL rearrangements in chronic myelogenous leukemia. Lab Invest 95(Suppl 1):384A, 2015. e-Pub 2015.
Liu W, Lu G, Liu H, Young KH, Tang G, Fayad L, Medeiros LJ, Hu S. MYC/8q24 deletion in diffuse large B-cell lymphoma. Lab Invest 95(Suppl 1):360A, 2015. e-Pub 2015.
Goswami RS, Liang CS, Hu S, Medeiros LJ, Tang G. Isolated trisomy 15 in bone marrow: disease-associated or a benign finding?. Lab Invest 95(Suppl 1):347A, 2015. e-Pub 2015.
Li Y, Hu S, Zuo Z, Hong M, Lin P, Li S, Konoplev S, Wang Z, Khoury JD, Young KH, Medeiros LJ, Yin CC. CD5-positive follicular lymphoma, clincopathologic correlations and outcome in 88 cases. Lab Invest 95(Suppl 1):359A, 2015. e-Pub 2015.
Rich A, Ai A, You MJ, Yin CC, Bueso-Ramos CE, Medeiros LJ, Hu S. Pediatric chronic myelogenous leukemia in tyrosine kinase inhibitor era. Lab Invest 95(Suppl 1):373A, 2015. e-Pub 2015.
Pan Z, Xu J, Siegele BJ, Kolfenbach J, Reddy VV, Schowinsky J, Hu S. A significant increase in IgG4+ cells is a common finding in reactive lymph nodes of unknown etiology. Lab Invest 94(Suppl 1):369A, 2014. e-Pub 2014.
Loghavi S, Bueso-Ramos CE, Maiti SN, Hu S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper L, Zuo Z. Diagnostic and prognostic utility of plasma microRNA signatures in patients with myelodysplastic syndromes. Lab Invest 94(Suppl 1):359A, 2014. e-Pub 2014.
Hu S, Kim YS, Pan Z, Shahab I, Plaza, MC, Clubwala R, Medeiros LJ, Miranda RN. Lymphadenopathic systemic mastocytosis: a clinicopathologic report of 8 cases. Lab Invest 94(Suppl 1):352A, 2014. e-Pub 2014.
Hu S, Tzankov A, Visco C, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Piris MA, Møller MB, L Medeiros LJ, Young KH. MYC/BCL2 protein co-expression defines a unique subset of aggressive B-cell lymphomas and contributes to the inferior prognosis of activated B-cell subtype of diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Clin Lymphoma Myeloma Leuk 13(Suppl 2):S382-S383, 2013. e-Pub 2013.
Hu S, Tzankov A, Visco C, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Piris MA, Møller MB, L Medeiros LJ, Young KH. MYC/BCL2 protein co-expression defines a unique subset of aggressive B-cell lymphomas and contributes to the inferior prognosis of activated B-cell subtype of diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Lab Invest 93(Suppl 1):332A, 2013. e-Pub 2013.
Hu S, Tzankov A, Visco C, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Piris MA, Møller MB, L Medeiros LJ, Young KH. CD30-expression defines a novel subset of diffuse large B-cell lymphoma with superior clinical outcome: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Lab Invest 93(Suppl 1):332A, 2013. e-Pub 2013.
Hu S, Tzankov A, Visco C, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Piris MA, Møller MB, L Medeiros LJ, Young KH. Prognostic impact of MYC/BCL6 co-rearrangement and MYC/BCL6 co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Lab Invest 93(Suppl 1):333A, 2013. e-Pub 2013.
Madadi A, Raghavendra M, Hu S, Xu-Monette ZY, Visco C, Tzankov A, Montes-Moreno S, Dybkaer K, Chiu A, Ozazi A, Zu Y, Bhagat G, Dunphy CH, Hsi ED, Zhao FX, Choi WWL, Zhao X, JHJM VK, Huh J, Huang Q, Ai W, Ponzoni M, Ferreri AJM, Zhou F, Winter JN, Piris M, Moller MB, Medeiros LJ, Go RS, Young KH. Prognostic significance and phenotypic manifestations of MYC/BCL2 protein expression in diffuse large B-cell lymphoma (DLBCL) with extranodal organ involvement: A report of the International DLBCL Rituximab-CHOP Consortium Program study. Blood 120(21):544, 2012. e-Pub 2012.
Hu S, Ruvolo V, Lu H, Kantarjian HM, Wheeler D, Muzny DM, Medeiros LJ, Bueso-Ramos C, Konopleva M, Andreeff M, Konoplev S. HIF1a expression is associated with NPM1 mutation, but not IDH1 or IDH2 mutation in acute myeloid leukemia with normal karyotype. Lab Invest 92(Suppl 1):342A, 2012. e-Pub 2012.
Yin CC, Hu S, Medeiros LJ, Lu G. Isolated clonal trisomy 13 in Philadelphia chromosome-negative metaphases in patients with chronic myelogenous leukemia. Lab Invest 92(Suppl):383A, 2012. e-Pub 2012.
Hu S, Jimenez R, Ricci Jr A. Number of surgical excision needed to achieve pathologically negative margins and ultimate total mastectomy rates for invasive mammary carcinoma and DCIS in a nationally accredited breast center. Lab Invest 91(Suppl 1):43A-44A, 2011. e-Pub 2011.
Hu S, Fiel-Gan M, Mandavilli S. Diagnosis of squamous cell carcinoma of lung on cytology specimens in the era of novel chemotherapeutic agents. Lab Invest 90(Suppl 1):95A, 2010. e-Pub 2010.
Hu S, Sun Y, Brown A, Mandavilli S. Incidence of positive pelvic washings obtained during hysterectomy for endometrial adenocarcinoma: a comparison of robotic-assisted hysterectomy versus total abdominal hysterectomy. Lab Invest 90(Suppl 1):247A, 2010. e-Pub 2010.
E S, Li S, Hu S, Guo M, Xu J, Medeiros LJ, Lin P. Adult onset familial hemophagocytic lymphohistiocytosis with heterozygous mutations of PRF1 and STXBP2 following CAR-T therapy for diffuse large B cell lymphoma. European Association of Hematopathology - Society of Hematopathology Workshop.
Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian KM, Medeiros LJ, Hu S. Risk stratification of additional chromosomal changes in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Texas Society of Pathology 95th Annual Meeting.
Chen Z, Wang W, Medeiros LJ, Hu S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy.
Wang W, Chen Z, Hu Z, Yin CC, Li S, Bai S, Bueso-Ramos CE, Medeiros LJ, Hu S. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy.
Gong Z, Chen Z, Wang W, Medeiros LJ, Hu S. Role of additional chromosomal alterations in chronic myeloid leukemia with variant Philadelphia translocations in the era of tyrosine kinase inhibitor therapy. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy.
Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Chromosomal aberrations causing MECOM rearrangement in myeloid malignancies: analysis of 129 cases. American College of Medical Genetics.
Fang H, Hu S, Medeiros LJ, Wang SA. T-acute lymphoblastic leukemia with aberrant expression of B-cell markers. European Association of Hematopathology - Society of Hematopathology Workshop.
Wang WJ, Chen L, Hu S, Hu Z. HHV8-negative primary effusion lymphoma in a patient with a liver transplant. European Association of Hematopathology - Society of Hematopathology Workshop.
Naik U, Wang WJ, Ali H, Nguyen A, Hu S, Wang W, Hu Z. Nodal marginal zone lymphoma with T-follicular helper expansion in a patient with a history of subcutaneous panniculitis-like T-cell lymphoma. European Association of Hematopathology - Society of Hematopathology Workshop.
Wang SA, Ok CY, Hu S, Bueso-Ramos CE. T-lymphoblastic lymphoma/leukemia with expression of TCRγδ and a mature immunophenotype. European Association of Hematopathology - Society of Hematopathology Workshop.
He H, Yu F, Nastoupil LJ, Xu-Monette ZY, Pham K, Yin CC, Yang Y, Hu S, Young KH, Pham LV, You MJ. Dysregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Experimental Hematopathology Scientific Symposium, MDACC.
Thakral B, Hu S, Wang W, Muzzafar T, Medeiros LJ, Wang SA. CD123-negative BRAF-negative Hairy cell leukemia. European Association of Hematopathology - Society of Hematopathology Workshop.

Book Chapters

Apperley JF, Cortes J, Cross NCP, Godley LA, Hu S, Naresh KN, Radich JP, Rousselot P, Subramanian PG. Chronic myeloid leukemia. In: Haematolymphoid Tumors. 5th. World Health Organization, 2024.
Hu S, Haferlach T, Hodge JC, Khattry N, Orgel E, Radich JP. Mixed-phenotype acute leukemia with BCR::ABL1 fusion. In: Haematolymphoid Tumors. World Health Organization, 2024.
Hu S, Haferlach T, Hodge JC, Khattry N, Radich JP. Acute myeloid leukemia with BCR::ABL1 fusion. In: Haematolymphoid Tumors. World Health Organization, 2024.
Nardi V, Cassaday RD, Cazzaniga G, Harris MH, Hu S, Leventaki V, Weinstock DM. B-lymphoblastic leukemia/lymphoma with BCR::ABL1 fusion. In: Haematolymphoid Tumors. World Health Organization, 2024.
Zhou T, Hu S. Chronic Myeloid Leukemia. In: Practical Lymph Node and Bone Marrow Pathology: Frequently Asked Questions. 1st. Springer, 2020.

Less

CV information above last modified March 06, 2026

Shimin Hu, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Abstracts

Book Chapters

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Shimin Hu, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson